Document:

<PAGE>

                                                                    EXHIBIT 4.11

                               G.D. SEARLE & CO.

                  CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC/1/
                        RESEARCH AND LICENSE AGREEMENT

THIS AGREEMENT (the "AGREEMENT") effective as of the last date of signature
hereto (the "EFFECTIVE DATE") between:

     G.D. SEARLE & CO., (hereinafter referred to as "SEARLE"), a company
organized and existing under the laws of the State of Delaware having its
principal place of business at 5200 Old Orchard Road, Skokie, Illinois 60077.
SEARLE is a wholly owned subsidiary of MONSANTO COMPANY, also a company
organized and existing under the laws of the State of Delaware. MONSANTO
COMPANY's registered securities are primarily traded in the United States on the
New York Stock Exchange and are subject to such exchange's rules.

     and

     CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, (hereinafter referred to as "CAT"),
a corporation organized and existing under the laws of England, with its
principal place of business at The Science Park Melbourn Cambridgeshire England
SG8 6JJ.

                                  WITNESSETH:

     WHEREAS, CAT owns or has licenses to practice and independently develop
various technologies, including but not limited to phage display libraries of
fully human antibody sequences, appropriate for:

     1) the discovery, characterization, and optimization of (a) biological
        proofs of principle or (b) therapeutic drug TARGETS;

     2) the discovery, characterization, optimization, manufacture and/or
        registration of fully human antibodies, and analogues and fragments
        thereof, as therapeutic drugs against identified TARGETS; and

     3) the discovery, characterization and further description of TARGETS for
        the optimal discovery and development of synthetic molecules for
        pharmaceutical applications against such TARGETS;

     WHEREAS, CAT is the owner or licensee of intellectual property with rights
to practice and/or sub-license to SEARLE the rights to use such intellectual
property for the purposes of the characterization of biological processes, the
identification of drug TARGETS, the

_____________________
/1/  [***] indicates that text has been deleted, which is subject to a
confidential treatment request. This text has been filed with the SEC on a
supplemental basis.
<PAGE>

discovery and development of ANTIBODY BASED DRUG candidates, and the other
purposes contemplated under the terms of this AGREEMENT;

     WHEREAS, SEARLE wishes to obtain licenses to use such intellectual property
on the terms hereinafter stated
     1)  to discover and characterize TARGETS and
     2)  to develop exclusively LICENSED PRODUCTS against specific TARGETS as
         may be permitted by this AGREEMENT; and

     WHEREAS, CAT is willing to grant such licenses to SEARLE under the terms
and conditions of this AGREEMENT.

     NOW, THEREFORE, in consideration of these premises and the mutual promises
recited herein the parties, intending to be bound, agree as follows:

                            ARTICLE 1 - DEFINITIONS

     For the purpose of use in or related to this AGREEMENT, the following terms
shall be defined as follows:

1.1  "AFFILIATE" shall mean any corporation, partnership or other entity which
     owns or controls, is owned or controlled by or is under common ownership or
     control with a party to this AGREEMENT. Control shall mean the possession
     of fifty percent (50%) or more (twenty percent (20%) or more for purposes
     of Sections 1.48, 2.1(b) and 4.11) of the voting stock or the power to
     direct or cause the direction of management and policies of the controlled
     entity, whether through the ownership of shares or by contract or
     otherwise.

1.2  "ANTIBODY" shall mean a molecule or a gene encoding such a molecule
     identified or developed during the RESEARCH COLLABORATION which comprises
     or contains one or more human immunoglobin variable domains or parts of
     such domains or any existing or future fragments thereof.

1.3  "ANTIBODY BASED DRUG" shall mean a product which comprises an ANTIBODY for
     any discovery, diagnostic, therapeutic or other medical use.

1.4  "BIOLOGICAL PATHWAY" shall mean an intra-cellular series of molecular
     targets of which a minimum number of molecular targets are known and
     demonstrated by repeatable experiment to be involved in a specific signal
     transduction cascade in a specific cell type and leading to a specific
     cellular or other physiological event or effect. For the avoidance of doubt
     BIOLOGICAL PATHWAY shall not include extracellular or cell surface
     transmembrane molecular targets.

                                       2
<PAGE>

1.5  "BLA FILING" shall mean a Biologic License Application, or other
     application for the approval of marketing of any LICENSED PRODUCT, which is
     submitted to the FDA in a MAJOR MARKET.

1.6  "BUSINESS DAY" shall mean a day other than a Saturday, Sunday, bank or
     other public holiday in London, England or Chicago, Illinois, United
     States.

1.7  "CAT" shall mean CAT and its AFFILIATES from time to time.

1.8  "CAT BACKGROUND IP" shall mean the IP including the LICENSED PATENTS and
     related MATERIALS and property rights in such MATERIALS owned by or
     licensed to CAT, with the right to grant sublicenses, comprising or
     relating to the CAT CORE TECHNOLOGY.

1.9  "CAT BACKGROUND KNOW HOW" shall mean the KNOW HOW included as part of the
     CAT BACKGROUND IP.

1.10 "CAT BACKGROUND MATERIAL" shall mean MATERIAL which directly relates to an
     ANTIBODY or to the CAT SUBTRACTED LIBRARIES and which is owned by or
     licensed to CAT.

1.11 "CAT BACKGROUND PATENT RIGHTS" shall mean the PATENT RIGHTS (including the
     LICENSED PATENTS) included as part of the CAT BACKGROUND IP.

1.12 "CAT IMPROVEMENT IP" shall mean any IMPROVEMENTS to any part of the CAT
     BACKGROUND IP that arise in the ordinary course of performance of research
     by CAT during the term of this AGREEMENT, except that it shall not include
     new techniques which were developed solely due to the collaboration with
     SEARLE and use SEARLE'S BACKGROUND IP. For the avoidance of doubt, CAT
     IMPROVEMENT IP shall not include any ANTIBODY. All ANTIBODIES shall be
     considered RESEARCH COLLABORATION IP and shall be owned by SEARLE.

1.13 "CAT LIBRARY TECHNOLOGY" shall mean the collection of bacteriophages each
     of which displays an antibody or a collection of host cells containing such
     collection of bacteriophages possessed by CAT as of the date SEARLE
     exercises its option pursuant to Section 2.8.

1.14 "CAT SUBTRACTED LIBRARY" shall mean (a) the [***] subtracted angiogenesis
     [***] Libraries and (b) the [***] subtracted haemotopoiesis [***] Libraries
     owned by CAT at the EFFECTIVE DATE as more particularly described in
     Exhibit B.

1.15 "CAT TARGET" shall mean a TARGET which is identified or developed in whole
     or in part as a consequence of SEARLE's sequencing of CAT MATERIALS in any
     CAT

                                       3
<PAGE>
     characterization of drug TARGETS, the SUBTRACTED LIBRARIES pursuant to
     Article 5 of this AGREEMENT. For the avoidance of doubt, [***] shall be
     deemed a CAT TARGET for the purposes of this AGREEMENT.

1.16 "CAT CORE TECHNOLOGY" shall mean any proprietary information, methods,
     MATERIALS, processes, techniques, and formulae which relate to the CAT
     SUBTRACTED LIBRARIES or which CAT requires to carry out its part of the
     RESEARCH COLLABORATION and which are owned by or licensed to CAT either at
     the EFFECTIVE DATE or which arise at any time during the term of this
     AGREEMENT (whether pursuant to it or otherwise) including IMPROVEMENTS. CAT
     CORE TECHNOLOGY does not include (i) SEARLE TARGETS, (ii) proprietary
     research tools, technologies or research methods of SEARLE used to make
     antibody-based or related physiologic or pharmacokinetic discoveries or
     antibody formulations, (iii) antibody process development and/or
     manufacturing technologies with respect to antibody based drugs, or (iv)
     other ideas, concepts, or INVENTIONS of SEARLE that are independent of or
     not related to the RESEARCH COLLABORATION.

1.17 "COLLABORATION YEAR" shall mean each successive twelve (12) calendar month
     period commencing with the initiation of research efforts as defined in
     Section 1.50.

1.18 "COMBINATION PRODUCT" shall mean a LICENSED PRODUCT containing an ANTIBODY
     BASED DRUG which also:

       contains an active ingredient that is not within the scope of CAT
       BACKGROUND IP or SEARLE BACKGROUND IP as each exists as of the EFFECTIVE
       DATE; or

       is administered through an active administration technology that is not
       within the scope of CAT BACKGROUND IP or SEARLE BACKGROUND IP as each
       exists as of the EFFECTIVE DATE; or

       operates with a diagnostic detection mechanism that is not within the
       scope of CAT BACKGROUND IP or SEARLE BACKGROUND IP as each exists as of
       the EFFECTIVE DATE;

       and such other elements shall each be referred to individually or
       collectively as an "OTHER ELEMENT".

1.19 "COMPETENT AUTHORITY" shall mean any national or local agency, authority,
     department, inspectorate, minister, ministry official, parliament or public
     or statutory person (whether autonomous or not) of any government having
     jurisdiction over the approval for marketing and sale of any pharmaceutical
     product.

                                       4
<PAGE>

1.20 "DIAGNOSTIC PRODUCT" shall mean any product in the form of a device,
     compound, kit or service with utility in the diagnosis, prognosis,
     prediction or monitoring of progress of a disorder (i) incorporating part
     of at least one variable region of an ANTIBODY or (ii) which was developed
     based on biological activity identified by an ANTIBODY and whose potential
     medical utility was first demonstrated by an ANTIBODY to a TARGET and whose
     sale but for the licenses granted by CAT hereunder would infringe a VALID
     CLAIM or CAT BACKGROUND PATENT RIGHTS.

1.21 "DOCUMENTS" shall mean reports, research notes, charts, graphs, comments,
     computations, analyses, recordings, photographs, paper, notebooks, books,
     files, ledgers, records, tapes, discs, diskettes, CD-ROM, computer programs
     and documents thereof, computer information storage means, samples of
     material, other graphic or written data and any other media on which KNOW
     HOW can be permanently stored.

1.22 "EST" shall mean an expressed sequence tag.

1.23 "FDA" shall mean the United States Food and Drug Administration or any
     successor agency thereto or the equivalent COMPETENT AUTHORITY in any other
     country.

1.24 "FIELD" shall mean any disease code under ICD9 (1999), as the same may be
     amended.

1.25 "FIRST COMMERCIAL SALE" shall mean the first commercial sale by SEARLE or
     its sub-licensees in any country of a LICENSED PRODUCT after grant of
     required MARKETING AUTHORISATION and pricing approval by the appropriate
     COMPETENT AUTHORITY.

1.26 "FLG" shall mean a full length gene.

1.27 "FULL TIME HEADCOUNT EQUIVALENT" or "FTE" shall mean the amount of
     professional laboratory research and/or development work as would
     reasonably be performed in a full employment month, quarter, or year, as
     applicable, in the United Kingdom by a fully trained, professionally
     qualified, full time CAT researcher expert in the operation of any one of
     the various expertises as may be necessary or desirable for performance of
     the RESEARCH PROTOCOL. Such expertises shall include any particular areas
     of CAT's functional genomics and proteomics platform technologies available
     now or becoming available at any time during the course of the
     collaboration including the development, maintenance or use of CAT's phage
     display antibody libraries, data base management, data mining, ProAbJ and
     ProxiMol7 and such other antibody-based screening, TARGET characterization,
     antibody optimization, antibody production, antibody scale-up solely to
     support development work to achieve Section 4.3 milestones, or testing
     abilities as SEARLE determines useful or desirable for biological research
     and/or drug discovery in accordance with the RESEARCH PROTOCOL.

                                       5
<PAGE>

1.28 "GOOD CLINICAL PRACTICE" shall mean clinical practice as set out in:

     (1)  ICH Harmonized Guidance on Good Clinical Practice (CPMP/ICH/135/95);

     (2)  US Code of Federal Regulations Title 21, Chapters 50 (Protection of
          Human Subjects) and 56 (Institutional Review Boards), as may be
          amended from time to time; and

     (3)  the equivalent law or regulation in any MAJOR MARKET.

1.29 "GOOD LABORATORY PRACTICE" shall mean laboratory practice as set out in:

     (1)  Rules in force in the European Union relating to GLP, including EC
          Directives 87/18/EEC, 88/320/EEC and 1999/11/EC;

     (2)  US Code of Federal Regulations, Title 21, Chapter 58 (Good Laboratory
          Practice for Nonclinical Laboratory Studies) where applicable; and

     (3)  the equivalent law or regulation in any MAJOR MARKET.

1.30 "GOOD MANUFACTURING PRACTICE" shall mean manufacture in accordance with:

     (1)  EC Directive 91/356/EEC;

     (2)  the current principles and guidelines of good manufacturing practice
          for medicinal products for human use and "in substantial conformity
          with good manufacturing requirements" (as such phrase is used in
          Section 802(f)(l) of the Federal Food, Drug and Cosmetic Act, as such
          Act may be amended from time to time); and

     (3)  the equivalent law or regulation in any MAJOR MARKET.

1.31 "IMPROVEMENTS" shall mean any improvements, modifications and adaptations
     (whether patentable or otherwise) primarily and directly relating to any
     part of the CAT BACKGROUND IP or the SEARLE BACKGROUND IP, as the case may
     be, which may arise in connection with, and during the term, of this
     AGREEMENT.

1.32 "INDEPENDENT COUNSEL" shall mean a member of a firm of patent attorneys,
     licensed to practice before the United States Patent and Trademark Office,
     selected by the parties (as stated in Section 6.3) from time to time during
     the term of this AGREEMENT to resolve TARGET acceptability for RESEARCH
     PROGRAM and exclusivity disputes pursuant to Article 2 and 3 hereof. The
     parties initially designate [***] as INDEPENDENT COUNSEL.

                                       6
<PAGE>

1.33 "IN-HOUSE RESEARCH" shall mean research activities controlled by SEARLE,
     whether using internal resources or those of third parties provided that
     any such third party is an academic institution, a contract research
     organisation, hospital or clinic or other similar institution involved in
     assisting with a clinical trial, and undertaken solely for the purposes of
     developing or creating SEARLE INVENTIONS and/or products. For other
     entities SEARLE shall obtain prior written approval from CAT such approval
     not to be unreasonably withheld. Upon written request from CAT SEARLE shall
     provide a list of third parties covered by this definition.

1.34 "IP" shall mean PATENT RIGHTS and KNOW HOW.

1.35 "INVENTION" shall mean any and all legally protectable or enforceable
     industrial or intellectual property rights, including, but not limited to
     any ideas (whether novel or not), or combination of ideas, conceptions,
     reductions to practice, patents (including all rights to grant licenses,
     and sub-licenses thereon, continuations, reissues, divisions, patent
     applications, and rights to patent), trade secrets, trademarks, trade
     dress, KNOW HOW, methods of business, regulatory filing rights, or market
     exclusivity rights (whether based upon patent, KNOW-HOW, registration
     delay, or other rights), conferring commercial exclusivity or rights of
     product registration recognized, permitted and/or enforced by any action of
     law, regulation or administrative authority under any law of any country in
     the TERRITORY.

1.36 "JOINT RESEARCH COMMITTEE" or "JRC" shall mean the working committee to be
     established by the parties pursuant to Article 3 in order to implement the
     provisions of this AGREEMENT in an orderly manner.

1.37 "KNOW HOW" shall mean unpatented technical and other information which is
     not in the public domain, including information comprising or relating to
     concepts, discoveries, data, designs, formulae, ideas, information relating
     to MATERIAL, [methods, models, assays, research plans, procedures, designs
     for experiments and tests and results of experimentation and testing
     (including results of research or development), processes (including
     manufacturing processes, specifications and techniques), laboratory
     records, chemical, pharmacological, toxicological, clinical, analytical and
     quality control data, trial data, case report forms, data analyses,
     reports, manufacturing data or summaries and information contained in
     submissions to and information from ethical committees and regulatory
     authorities. KNOW HOW includes DOCUMENTS containing KNOW-HOW. The fact that
     an item is known to the public shall not be taken to exclude the
     possibility that a compilation including the item, and/or a development
     relating to the item, is not known to the public. KNOW HOW includes any
     rights (such as copyright, database or design rights) protecting such KNOW
     HOW. In the case of CAT, KNOW HOW shall also include ProAb and ProxiMol and
     other antibody identification and research related tools or technologies as
     more particularly described in Exhibit E.

                                       7
<PAGE>

1.38 "LIST" shall mean a list of a maximum number of [***] TARGETS (including
     TARGETS and BIOLOGICAL PATHWAYS, each of the two (2) foregoing defined
     terms being a separate single TARGET for purposes of calculating the
     foregoing number) prepared by SEARLE (the initial such LIST being set out
     in EXHIBIT F) as such LIST may be amended by SEARLE from time to time
     during the term of the RESEARCH COLLABORATION upon written notification to
     CAT subject to the provisions of Article 6. The LIST shall contain up to
     [***] TARGETS on Part A of the LIST. The balance shall be designated Part
     B.

1.39 "LICENSED PATENTS" shall mean the patents and patent applications
     identified in Exhibit A, any foreign counterparts thereof, as well as all
     continuations, continuations-in-part, divisions, reissues, and renewals
     thereof; all patents, both US and foreign, which may be granted thereon;
     and all reissues, reexaminations, extensions, patents of addition, patents
     of information thereof; and any additional patents held by CAT as of the
     date of this AGREEMENT or as may be owned by CAT or licensed to CAT during
     the term of this AGREEMENT comprising or relating to the CAT CORE
     TECHNOLOGY.

1.40 "LICENSED PRODUCT" shall mean (i) an ANTIBODY BASED DRUG or DIAGNOSTIC
     PRODUCT isolated under a process which would but for the license granted in
     Section 2 infringe a VALID CLAIM of an enforceable LICENSED PATENT or the
     manufacture use or sale of which by SEARLE would, but for the license
     granted in Section 2 infringe a VALID CLAIM of an enforceable LICENSED
     PATENT or (ii) a SYNTHETIC DRUG or (iii) a product which would otherwise
     give rise to a royalty obligation from CAT to the MRC under the license
     agreement dated 7 January 1997.

1.41 "VALID CLAIM" shall mean a claim of any issued or granted, unexpired
     LICENSED PATENT which has not been held invalid or unenforceable by a non-
     appealed or unappealable decision by a court or other appropriate body of
     competent jurisdiction, including arbitration proceedings.

1.42 "MAJOR DEAL" shall mean any agreement commitment or arrangement with
     respect to the FIELD of [***] where CAT would agree to engage in a research
     effort with a third party which is intended to be or by its terms could be
     exclusive. For purposes of this Section only, "exclusive" at any time means
     that the agreement, commitment, or arrangement covers at least a majority
     of known TARGETS with respect to the FIELD of [***], excluding for that
     purpose [***].

1.43 "MAJOR MARKET" shall mean the United States of America, France, Germany,
     Italy, Japan, Spain, or the United Kingdom and if required by European law
     the European Union acting through the EMEA or its successor.

                                       8
<PAGE>

1.44 "MARKETING AUTHORISATION" shall mean any approval required from a COMPETENT
     AUTHORITY to market and sell a LICENSED PRODUCT in any country.

1.45 "MARKETING YEAR" shall mean each successive twelve (12) calendar month
     period commencing with the FIRST COMMERCIAL SALE of a LICENSED PRODUCT.

1.46 "MATERIAL" shall mean any chemical or biological substances, any organic or
     inorganic element or compound, nucleotide, single nucleotide polymorphism
     ("SNPS") and precursors thereof, or nucleotide sequence (including DNA and
     RNA sequences, gene, vector or construct including plasmids, or viruses),
     host organism (including fungi, algae, protozoa and hybridomas, eukaryotic
     or prokaryotic cell line or expression system or any development strain or
     product of that cell line or expression system), protein (including any
     peptide or amino acid sequence, enzyme, antibodies or protein conferring
     targeting properties and any fragment of a protein or a peptide enzyme or
     antibody), drug or pro-drug, assay or reagent, or any other genetic or
     biologic material or micro-organism or multi-cellular plants.

1.47 "MRC" shall mean The Medical Research Council or any successor body
     thereto.

1.48 "NET SALES" shall mean the revenue received by SEARLE or its AFFILIATE
     from the sale of LICENSED PRODUCTS to independent third parties less the
     following amounts:

     (1)  any discounts, including cash discounts, or rebates actually allowed
          or granted (including discounts required under government programs);

     (2)  any applicable credits, allowances, and returns;

     (3)  sales, excise, turnover, value-added or similar taxes or duties
          actually levied on the manufacture or sale of LICENSED PRODUCT and
          included in the gross amount billed; and

     (4)  transportation, insurance, and handling charges as determined in
          accordance with generally accepted accounting principles.

          In the event that LICENSED PRODUCTS are sold in the form of
          COMBINATION PRODUCTS containing one or more active ingredients, other
          than the LICENSED PRODUCT, NET SALES for such COMBINATION PRODUCTS
          will be calculated by the fraction A/(A+B), where A is the invoice
          price of the LICENSED PRODUCT if sold separately, and B is the total
          invoice price of any OTHER ELEMENTS in combination, if sold separately
          by SEARLE or its AFFILIATE.

                                       9
<PAGE>

          If the average sale price of ANTIBODY BASED DRUG or SYNTHETIC DRUG can
          be determined but the average sale price of the OTHER ELEMENT in that
          product cannot be determined NET SALES for the COMBINATION PRODUCT in
          any applicable country for purposes of determining royalty payments
          shall be calculated by multiplying the NET SALES of the COMBINATION
          PRODUCT in that country by the fraction C/(C+D) where C is the selling
          party's average sales price in the preceding quarter of the ANTIBODY
          BASED DRUG OR SYNTHETIC DRUG and D is the difference between the
          average selling price in the preceding quarter of the COMBINATION
          PRODUCT and the average selling price in the preceding quarter of the
          applicable LICENSED PRODUCT in that country.

          If the average sale price of the OTHER ELEMENT in that quarter can be
          determined but the average price of ANTIBODY BASED DRUG OR SYNTHETIC
          DRUG cannot be determined, NET SALES for purposes of determining
          royalty payments for the COMBINATION PRODUCT in that country shall be
          calculated by multiplying the NET SALES of the COMBINATION PRODUCT in
          that country by the following formula: one (1) minus C/(C+D) where C
          is the average selling price in the preceding quarter of the OTHER
          ELEMENT in that country and D is the difference between the average
          selling price of the COMBINATION PRODUCT and the average selling price
          of the OTHER ELEMENT.  In the event that the average sale price of
          both ANTIBODY BASED DRUG or SYNTHETIC DRUG and the OTHER ELEMENT in
          the COMBINATION PRODUCT cannot be determined, the NET SALES of
          ANTIBODY BASED DRUG OR SYNTHETIC DRUG shall be determined by an
          arbitrator pursuant to Exhibit D.

1.49 "PATENT RIGHTS" shall mean patent applications and patents, author
     certificates, inventor certificates, utility certificates, improvement
     patents and models and certificates of addition and all foreign
     counterparts of each of them, including any divisional applications and
     patents, refilings, renewals, continuations, continuations-in-part, patents
     of addition, extensions, reissues, substitutions, confirmations,
     registrations, revalidation and additions of or to any of them, as well as
     any supplementary protection certificates and equivalent protection rights
     in respect of any of them.

1.50 "RESEARCH COLLABORATION" shall mean the collaborative research effort
     contemplated in this AGREEMENT. The term of such research effort shall be
     not less than three (3) COLLABORATION YEARS (subject as otherwise provided
     in Article 13) from the initiation of research efforts pursuant to an
     agreed upon RESEARCH PROGRAM or PROGRAMS, initiation being deemed to occur
     the first full calendar quarter in which not less than [***] FTEs audited
     equivalents at CAT have performed research in accordance with the RESEARCH
     PROTOCOL as determined by the JRC.

                                       10
<PAGE>

1.51  "RESEARCH COLLABORATION IP" shall mean RESEARCH COLLABORATION PATENT
      RIGHTS, RESEARCH COLLABORATION KNOW HOW and RESEARCH COLLABORATION
      MATERIALS.

1.52  "RESEARCH COLLABORATION KNOW HOW" shall mean KNOW HOW conceived, generated
      or developed by or on behalf of the parties under the RESEARCH
      COLLABORATION.

1.53  "RESEARCH COLLABORATION MATERIALS" shall mean MATERIALS conceived,
      isolated, generated or developed by or on behalf of the parties under the
      RESEARCH COLLABORATION.

1.54  "RESEARCH COLLABORATION PATENT RIGHTS" shall mean PATENT RIGHTS claiming
      or covering or otherwise based on INVENTIONS forming part of RESEARCH
      COLLABORATION KNOW HOW, INVENTIONS comprised in RESEARCH COLLABORATION
      MATERIALS or INVENTIONS derived from or arising out of the RESEARCH
      COLLABORATION.

1.55  "RESEARCH PROTOCOL" shall mean all RESEARCH PROGRAMS proposed by SEARLE
      for a COLLABORATION YEAR, together with such additional non-TARGET
      specific schedules of work as shall be proposed by SEARLE for the same
      COLLABORATION YEAR. Each such RESEARCH PROTOCOL shall be adopted and
      amended and updated on a rolling basis to reflect changes in research and
      work progress in accordance with the terms of Article 3.

1.56  "RESEARCH PROGRAM" shall mean the schedule of work (which shall include
      cell biology and biochemical assays at a minimum) to be accomplished with
      respect to a specific TARGET as proposed by SEARLE to CAT not less than
      ninety (90) days prior to the end of each COLLABORATION YEAR of the
      RESEARCH COLLABORATION, including reasonable estimates of FTEs and FTE
      support necessary to accomplish the work forecasted in the schedule;
      provided that any such proposal for the initial COLLABORATION YEAR shall
      be made in the initial RESEARCH PROTOCOL attached hereto, as the same may
      be amended.

1.57  "SEARLE BACKGROUND IP" shall mean the IP and related MATERIALS and
      property rights in such MATERIALS owned by or licensed to SEARLE, with the
      right to grant sublicenses, comprising or relating to a SEARLE TARGET.

1.58  "SEARLE BACKGROUND KNOW HOW" shall mean the KNOW HOW included as part of
      the SEARLE BACKGROUND IP.

1.59  "SEARLE BACKGROUND PATENT RIGHTS" shall mean the PATENT RIGHTS included as
      part of the SEARLE BACKGROUND IP.

                                       11
<PAGE>

1.60  "SEARLE IMPROVEMENT IP" shall mean any IMPROVEMENTS to any part of the
      SEARLE BACKGROUND IP that may arise in connection with, and during the
      term of, this AGREEMENT, including new techniques developed using SEARLE's
      proprietary intellectual property relating to the use of the CAT
      BACKGROUND IP pursuant to this AGREEMENT which new techniques are not CAT
      IMPROVEMENT IP.

1.61  "SEARLE TARGET" shall mean a TARGET which is approved by the JRC for
      inclusion in any RESEARCH PROTOCOL.

1.62  "SIGNIFICANT PROGRAM"shall mean that CAT has an in house project in
      respect of a TARGET and as evidenced by its records has commenced an
      internal antibody engineering program or has committed substantive
      resource to such project equivalent to [***] within [***] prior to the
      identification of a TARGET.

1.63  "SUBSCRIPTION AGREEMENT" shall mean the agreement of even date herewith
      made between CAT's parent company, CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
      ("CAT GROUP"), and SEARLE'S AFFILIATE, Monsanto Europe S.A. relating to
      the subscription by such AFFILIATE for ordinary shares in CAT GROUP.

1.64  "SYNTHETIC DRUG" shall mean any protein, peptide, pepto-mimetic or other
      molecular form of compound (1) which is not an ANTIBODY BASED DRUG, (2)
      but which mimics in some fashion the structure activity relationship
      ("SAR") of ANTIBODIES identified through CAT phage display technology or
      an SAR which but for the CAT phage display technology, would have been
      significantly delayed (over twelve months) in development or would not
      have been developed at all, and (3) whose physiological and therapeutic
      effect was first predicted and first demonstrated by an ANTIBODY
      modulating such compound.

1.65  "TARGET" shall mean an individual biological molecule specified in writing
      together with appropriate accession number or other appropriate sequence
      information which may be a promising subject for the development of
      pharmaceutical products or diagnostics for the detection, prevention,
      treatment, palliation or amelioration of disease, for the improvement of
      the quality of life or the extension of the length of life. For the
      avoidance of doubt, [***].

1.66  "TERRITORY" shall mean all nations, protectorates and territories
      worldwide.

      In this AGREEMENT

(a)   unless the context otherwise requires all references to a particular
      Section, Exhibit or paragraph shall be a reference to that Section,
      Exhibit or paragraph, in or to this AGREEMENT as it may be amended from
      time to time pursuant to this AGREEMENT.

                                       12
<PAGE>

(b)  the table of contents and headings are inserted for convenience only and
     shall not affect the interpretation of any provision of this AGREEMENT;

(c)  unless the contrary intention appears words importing the masculine gender
     shall include the feminine and vice versa and words in the singular include
     the plural and vice versa;

(d)  unless the contrary intention appears words denoting persons shall include
     any individual, partnership, company, corporation, joint venture, trust,
     association, organization or other entity, in each case whether or not
     having separate legal personality;

(e)  reference to any statute or regulation includes any modification or
     reenactment of that statute or regulation; and

(f)  reference to the word "include" or "including" are to be construed without
     limitation to the generality of the preceding words.

               ARTICLE 2 - GRANT OF LICENSE; CONDITION PRECEDENT

2.1  Grant To SEARLE  Subject only to the exclusions stated in Section 2.2
     ---------------
     below, CAT hereby grants to SEARLE and its AFFILIATES:

(a)  a royalty-free, non-exclusive, worldwide right and license under the CAT
     BACKGROUND IP to the extent necessary or advisable (i) to perform SEARLE's
     obligations under the RESEARCH COLLABORATION and this AGREEMENT and (ii)
     for the purposes of IN-HOUSE RESEARCH, but not further or otherwise; and

(b)  an exclusive, perpetual, world-wide right and license, with the right to
     grant sub-licenses, under the CAT BACKGROUND IP necessary or advisable to
     make, have made, develop use, import, register, sell and have distributed
     in the TERRITORY LICENSED PRODUCTS.

2.2  Exclusions from Grant  During the term of the RESEARCH COLLABORATION, CAT
     ---------------------
     may perform discovery research and develop products against TARGETS for its
     own account and on behalf of third parties to the exclusion of the rights
     of SEARLE under the circumstances stated in Sections 2.3 and 2.4.,
     respectively. In the event of any dispute between CAT and SEARLE as to the
     application of Sections 2.3 and 2.4 to specific TARGETS such dispute shall
     be resolved pursuant to Exhibit D.

2.3  Research Under Way Prior to EFFECTIVE DATE  CAT may perform and retain
     ------------------------------------------
     exclusive rights to perform research and commercialize products against
     TARGETS:

[***]

                                       13
<PAGE>

2.4  Research Commenced After EFFECTIVE DATE  During the term of the RESEARCH
     ---------------------------------------
     COLLABORATION, CAT shall not perform research of any kind on behalf of or
     grant exclusive rights to any third parties in any TARGETs on the LIST
     subject to the terms of Section 6.2.

2.5  Grant License to CAT  SEARLE hereby grants to CAT a royalty-free, non-
     --------------------
     exclusive, worldwide license under the SEARLE BACKGROUND IP and the
     RESEARCH COLLABORATION IP to the extent necessary to perform CAT's
     obligations under the RESEARCH COLLABORATION and this AGREEMENT, but not
     further or otherwise for any other purpose and with no rights to grant sub-
     licenses or rights to assign such rights to third parties.

2.6  Limitation on Licenses  Save as expressly set out in this AGREEMENT nothing
     ----------------------
     in this AGREEMENT transfers or licenses any right, title or interest in or
     to the CAT BACKGROUND IP, the SEARLE BACKGROUND IP or the RESEARCH
     COLLABORATION IP.  Nothing in this AGREEMENT shall operate or be implied as
     a license to CAT or create in CAT any ownership of or claim of right to any
     SEARLE BACKGROUND IP or RESEARCH COLLABORATION IP for the purposes of
     commercializing any product independent of SEARLE.  SEARLE shall be the
     sole and entire owner of any intellectual property arising from the
     performance of the RESEARCH PROGRAMS and CAT shall not have or retain any
     rights of practice by joint inventorship or otherwise of any of the SEARLE
     BACKGROUND IP or the RESEARCH COLLABORATION IP

2.7  Condition Precedent  This AGREEMENT is conditional upon and shall be of no
     -------------------
     force and effect until the execution of the SUBSCRIPTION AGREEMENT.

2.8  Library Option Right  Within thirty (30) BUSINESS DAYS after the expiration
     --------------------
     or other termination of the RESEARCH COLLABORATION (excluding any
     termination due to SEARLE's default or bankruptcy), SEARLE may elect and
     CAT shall grant to SEARLE the right to utilize the CAT LIBRARY TECHNOLOGY
     for SEARLE's research purposes at SEARLE's sites.  Each such Site License
     (as defined below) includes:

(i)  transfer of the CAT LIBRARY TECHNOLOGY necessary for SEARLE to screen CAT's
     phage display libraries;

(ii) a non-exclusive, fully paid up, worldwide, sublicensable (to SEARLE
     collaborators for SEARLE IN-HOUSE RESEARCH) license to use such CAT LIBRARY
     TECHNOLOGY and any derivatives or progeny thereof for all research purposes
     (including any health care use) (each a "Site License").

                                       14
<PAGE>

2.9  Exercise of Right  Upon exercise by SEARLE of its rights set forth in
     -----------------
     Section 2.8 above by notice to CAT.

(a)  CAT shall promptly transfer the CAT LIBRARY TECHNOLOGY to SEARLE and

(b)  shall provide [***] of on-site technical support and training with respect
     to such CAT LIBRARY TECHNOLOGY at mutually agreeable times and SEARLE-owned
     or leased sites, each party agreeing not to unreasonably withhold agreement
     to such times and sites.

2.10 License Payment  As full consideration for:
     ---------------

(a)  CAT's grant to SEARLE of a Site License, and

(b)  CAT's transfer and technical support of such CAT LIBRARY TECHNOLOGY, as
     contemplated by Section 2.9 hereof;

     Searle will make licnese payment(s) as follows:

     [***]

     With respect to such payments, as applicable, [***] shall be paid to CAT
     upon exercise by SEARLE of its right to the Site License and the remaining
     [***] shall be payable upon completion of CAT's obligations as set forth in
     Section 2.9 hereof.

2.11 MAJOR DEAL
     ----------

(a)  For [***] from the EFFECTIVE DATE CAT shall notify SEARLE in writing at
     least [***] in advance of entering into any MAJOR DEAL, such notice to
     include the material elements of the proposed transaction other than the
     identity of the third party.

(b)  Provided that SEARLE so requests in writing within [***] of receiving such
     written notification as set out in (a), SEARLE and CAT shall enter into
     good faith negotiations with respect to the MAJOR DEAL for the remainder of
     such [***] period ("Negotiations Period").

(c)  Not less than [***] prior to the end of the Negotiations Period, CAT shall
     advise SEARLE of the terms and conditions upon which CAT is prepared to do
     the MAJOR DEAL or any variant thereof as may be developed by the parties
     ("LAST OFFER").  If SEARLE is prepared to match the terms of such LAST
     OFFER CAT may or may not at its option accept SEARLE's offer but may not
     consummate the MAJOR DEAL with the third party in question.

                                       15
<PAGE>

(d)  if SEARLE does not accept such LAST OFFER within [***] of the receipt
     thereof, CAT shall be free to consummate the MAJOR DEAL with the third
     party in question; provided that,

     (i)  such MAJOR DEAL is not on demonstrably better terms for the third
     party than CAT's LAST OFFER; and

     (ii) such consummation occurs within [***] of the expiration of the
     Negotiations Period.

(e)  If either of the conditions recited in (d) above are not complied with, CAT
     must notify SEARLE again of any such proposed MAJOR DEAL and comply with
     the remaining terms of this Section.

                      ARTICLE 3 - RESEARCH COLLABORATION

3.1  Research Goal  SEARLE and CAT seek to pursue an optimal collaboration for
     -------------
     the most rapid and robust development of efficacious pharmaceutical
     products.  SEARLE has tentatively determined a RESEARCH PROTOCOL which
     SEARLE believes offers an optimal chance, based upon available information
     and within the current technology and funding resources of SEARLE to
     develop such products.  The RESEARCH PROTOCOL for the first COLLABORATION
     YEAR will be delivered to CAT within thirty (30) days of the EFFECTIVE DATE
     and shall be deemed attached to this Agreement as Exhibit C.  Such RESEARCH
     PROTOCOL will thereafter be modified as stated in this AGREEMENT.

3.2  SEARLE Discovery Expenditures  SEARLE shall pay CAT the equivalent in
     -----------------------------
     English pounds of [***] per FTE for the performance of such research work
     in accordance with the terms of this AGREEMENT.  The applicable currency
     exchange rate shall be the rate published as of the last BUSINESS DAY of
     the applicable COLLABORATION YEAR quarter, determined in the same manner as
     set out in Section 4.13.  SEARLE shall exert its reasonable commercial
     efforts to perform and CAT agrees to exert its reasonable commercial
     efforts to perform the anticipated work in the RESEARCH PROTOCOL for each
     of the specified COLLABORATION YEARS in pursuit of TARGETS SEARLE shall
     have the sole discretion to utilize efforts in any RESEARCH PROTOCOL
     towards any discovery effort as it deems appropriate, regardless of the
     FIELD.  As of the date of this AGREEMENT, the estimates of FTEs required to
     achieve the work and objectives of the RESEARCH COLLABORATION during the
     first three (3) COLLABORATION YEARS are as follows:

     [***]

                                       16
<PAGE>

     Subject to the other terms and conditions of this AGREEMENT, SEARLE shall
     pay the above amounts for the applicable number of FTEs stated per
     COLLABORATION YEAR.  SEARLE shall endeavor to include reasonable matches of
     work objectives with forecasted FTE expenditures in each RESEARCH PROTOCOL,
     based upon productivity experience in prior RESEARCH PROTOCOLS and other
     CAT collaborations.  SEARLE shall have the ability on a quarter by quarter
     basis for each COLLABORATION YEAR to adjust and CAT shall so adjust, up or
     down, the number of FTEs dedicated to the RESEARCH COLLABORATION by [***]
     subject to maintaining the anticipated annual minimum aggregate payments as
     set out in the chart above.  CAT will use all reasonable efforts to
     accommodate any adjustments in excess of the [***] range described above,
     if and to the extent SEARLE requests same.  Notwithstanding the foregoing,
     in the event that FTEs exceed the minimums in the aggregate over the first
     two (2) COLLABORATION YEARS, any such excess shall be creditable against
     the minimum for the third such COLLABORATION YEAR.  [***]

3.3  SEARLE Election In The Event Work Not Accomplished Within The FTEs
     ------------------------------------------------------------------
     Estimated The foregoing notwithstanding, if the amount of the work done in
     ---------
     any one COLLABORATION YEAR is not or may not be accomplished with the
     amount of FTEs estimated, SEARLE may, but need not, pay such additional
     amount of FTE time at the full FTE rate as will reasonably accomplish the
     work required to achieve the goals forecasted in the RESEARCH PROTOCOL
     subject to C"T prior consent to provide such additional FTES such consent
     not to be unreasonably withheld.  SEARLE may elect to reduce such
     additional work as it may deem appropriate in later COLLABORATION YEAR work
     scheduled in the RESEARCH PROTOCOL as will offset any increased FTE
     expenditures required to perform work in earlier years.

3.4  CAT Staff Dedicated to Performance of RESEARCH PROTOCOL  At least thirty
     -------------------------------------------------------
     (30) days prior to the start of every COLLABORATION YEAR quarter other than
     the initial such quarter.  SEARLE and CAT management shall meet and
     determine which employees and which research services will be required in
     the upcoming quarter to achieve the reasonable objectives of the RESEARCH
     PROTOCOL ("QUARTERLY PLAN").  Such CAT staff as reasonably can dedicate
     their full time efforts, or at SEARLE's option such combination of CAT
     employees as may be able to combine their efforts to achieve the agreed
     work plan, shall be assigned to performance of RESEARCH PROTOCOL duties in
     accordance with such QUARTERLY PLAN.  SEARLE shall review the performance
     of such employees assigned to the RESEARCH PROTOCOL and may raise any
     concerns with the JRC.  If SEARLE reasonably determines that it wishes to
     replace a CAT employee CAT shall use reasonable endeavors to comply with
     SEARLE's request.

3.5  Payments Tied to Performance of Work  SEARLE shall pay CAT in arrears for
     ------------------------------------
     work performed hereunder on a quarter by quarter basis upon audit of
     services actually performed in such quarter.  CAT shall prepare and submit
     for SEARLE's review a report

                                       17
<PAGE>

     of work planned for the quarter and the work actually done during the
     quarter to determine the level of payment due. Payments shall be made upon
     demonstration that for each FTE required by quarter by the QUARTERLY PLAN,
     1/4th of the respective COLLABORATION YEAR FTE amount has been provided in
     such quarter in accordance with the QUARTERLY PLAN. Payments shall be made
     within sixty (60) days after receipt and acceptance by SEARLE, which
     acceptance shall not be unreasonably withheld, of the applicable quarterly
     report. Payment shall be made by wire transfer to the bank account in
     England designated from time to time by CAT in a written notice to SEARLE.

3.6  Audit of Tasks Accomplished and Time Required  In the event that the
     ---------------------------------------------
     parties disagree as to the level of performance of the QUARTERLY PLAN the
     parties shall require the review of an accounting referee in accordance
     with Exhibit D to determine the level of work done and the payments due.
     Either side may require an audit of the work performed upon request for the
     referee in accordance with Exhibit D.

3.7  Compensation of Dedicated CAT Staff  Employees performing services for
     -----------------------------------
     SEARLE shall be treated by CAT in terms of compensation and incentives in
     the same manner in all material respects to other CAT employees, taking
     into account all reasonable variances applied by CAT in determining the
     award of compensation and incentives to its employees generally.

3.8  Reductions in Compensation Forecasted by SEARLE In Event That CAT Fails to
     --------------------------------------------------------------------------
     Provide Adequate FTEs and Laboratory and Other Support for Such FTEs  In
     --------------------------------------------------------------------
     addition to any other remedy that SEARLE may have, in the event CAT fails
     to provide FTEs or laboratory and other resources estimated for performance
     of work in accordance with the RESEARCH PROTOCOL.  SEARLE's payments to CAT
     for FTEs supplied shall be reduced by [***], and SEARLE shall not be
     obliged to pay for any FTE to the extent that resources are not provided to
     support the reasonable performance of duties of any particular FTE.

3.9  CAT Consultation and Support  CAT shall at all times exert all reasonable
     ----------------------------
     creativity, judgment and research efforts on behalf of SEARLE in
     performance of the RESEARCH PROTOCOL.  CAT's efforts on behalf of SEARLE
     shall in no event be of less invention, less skill or of less favorable
     performance than the efforts of CAT's skilled persons working at CAT on
     matters similar to, but other than, the RESEARCH PROTOCOL or in any event
     no less than the standards of performance as meet regular professional
     standards in the pharmaceutical or biotechnology field.  Such efforts shall
     include but not be limited to:

     (a)  support in creation, identification and pursuit of intellectual
          property rights solely on SEARLE's behalf, including without
          limitation all INVENTIONS which are

                                       18
<PAGE>

          discovered incident to the RESEARCH PROTOCOL or in the course of any
          efforts undertaken by CAT at SEARLE expense;

     (b)  advice on the optimization of protocols and performance of research to
          be undertaken incident to the RESEARCH PROTOCOL;

     (c)  performance of all research and discovery services requested by SEARLE
          as part of the REACH PROTOCOL which may, at SEARLE's discretion, be
          part of any of CAT's general and specific expertise as of the time of
          this AGREEMENT or as may or should reasonably become part of CAT's
          general and specific expertise through the term of the performance of
          the RESEARCH PROTOCOL, including but not limited to (i) discovering,
          characterizing and/or quantifying pharmaceutically or diagnostically
          interesting molecules, (ii) discovering and characterizing biological
          responses to TARGETs, to antagonism of TARGETs or to agonism of
          TARGETs, (iii) discovering, optimizing, developing and/or registering
          therapeutic drug candidates, whether peptide, protein, antibody or
          synthetic molecule based, as may directly or indirectly, inhibit,
          antagonize, agonize or mimic TARGETs and (iv) to discovering (as may
          be suitable either for additional research or as drug TARGETs in
          themselves) the biological effect of neutralization of biological
          markers or TARGETs.

3.10 SEARLE Election In The Event Work Accomplished With Fewer Than Estimated
     ------------------------------------------------------------------------
     FTEs  The foregoing notwithstanding, if the amount of the work done in any
     ----
     one COLLABORATION YEAR is accomplished or may be reasonably forecasted to
     be accomplished with less than the estimated FTEs, SEARLE with approval of
     JRC may, but need not, increase the work planned in such year to absorb the
     planned areas of pay for such additional amount of FTE time at the full FTE
     rate specified in Section 3.2.

3.11 Management of the RESEARCH COLLABORATION  From the EFFECTIVE DATE, the
     ----------------------------------------
     parties shall establish and run the JOINT RESEARCH COMMITTEE as follows:

     (a)  The JRC shall be comprised of six (6) persons ("Members").  CAT and
          SEARLE, respectively, shall each be entitled to appoint three (3)
          Members, to remove any Member appointed by such party and to appoint
          any person to fill a vacancy arising from the removal or retirement of
          any such Member.  The initial members of the JRC shall be as follows:

               CAT Member      SEARLE Member
               ----------      -------------

               [***]               [***]

                                       19
<PAGE>

     (b)  SEARLE and CAT, respectively, shall each notify the other in writing
          of the identities of their respective Members or Member designees from
          time to time.  Both parties shall use reasonable endeavors to keep an
          appropriate level of continuity in representation.  Members may be
          represented at any meeting by another person designated by the absent
          Member.  Each meeting shall be chaired by one of the SEARLE Members
          ("Chairman").

     (c)  The quorum for meetings of the JRC shall be two Members or Member
          designees, provided that there is at least one Member or designee
          appointed by each of SEARLE and CAT present.  Conclusions and
          decisions of the JRC shall be made where possible by unanimous
          agreement of the Members or designees present and shall be minuted by
          or upon behalf of the Chairman who shall send a copy of the minutes of
          each JRC meeting to both parties.  Both parties will use their
          reasonable efforts to build consensus.  Should it prove impossible to
          obtain such consensus the Chairman shall have the deciding vote,
          subject in all events to the other terms and conditions of this
          AGREEMENT.  For avoidance of doubt, the Chairman shall not have the
          deciding vote as to any issues between the parties directly
          concerning:

          (i)   whether CAT has earned a Technical Performance Milestone under
                Section 4.3;

          (ii)  whether CAT has earned a Development Milestone under Section
                4.6; or

          (iii) Article 5 of this AGREEMENT.

     (d)  The JRC shall first meet within twenty (20) BUSINESS DAYS following
          the EFFECTIVE DATE and then as agreed by the Members, but not less
          frequently than each calendar quarter.  The venue for all meetings
          shall alternate between the premises of the parties.  Each party shall
          be responsible for its own expenses, including travel and
          accommodation costs, incurred in connection with JRC meetings.

     (e)  The JRC shall have power to invite persons whose special skills or
          influence might advance the RESEARCH COLLABORATION to attend and
          address meetings of the JRC.  For the avoidance of doubt, it is agreed
          that such persons shall not be Members and shall not have a right to
          participate in the decision-making process of the JRC.

     (f)  Within five (5) BUSINESS DAYS of each meeting of the JRC the Chairman
          shall prepare or have prepared minutes of the meeting and shall
          circulate the same as a draft by facsimile or E-mail to the other
          Members.  Such other Members shall have five (5) BUSINESS DAYS to send
          their written comments (including

                                       20
<PAGE>

          proposed amendments) on the draft minutes to the Chairman, and the
          Chairman shall promptly incorporate all such reasonable and accurate
          amendments. The Chairman shall then promptly sign the amended version
          of such minutes and shall circulate the same by facsimile or E-Mail to
          the other Members.

3.12 JRC Function and Responsibilities  The JRC shall be generally responsible
     ---------------------------------
     for administering the implementation of the RESEARCH PROTOCOLS in
     compliance with this AGREEMENT.  One function of the JRC shall be to
     nominate and select T"RGETS for inclusion in the RESEARCH PROTOCOLS or
     RESEARCH PROGRAMS.  TARGETS shall be deemed identified for purposes of
     Section 2.4 if contained on the LIST.

3.13 Disclosure  Promptly, but in no event later than thirty (30) days
     ----------
     following the EFFECTIVE DATE, CAT shall disclose and make available to
     SEARLE such of the CAT BACKGROUND KNOW HOW and CAT BACKGROUND MATERIAL as
     will be useful and necessary to SEARLE for the part of the RESEARCH
     COLLABORATION to be undertaken by SEARLE and SEARLE shall disclose and make
     available to CAT such of the SEARLE BACKGROUND KNOW HOW and SEARLE
     BACKGROUND MATERIAL as will be useful and necessary to CAT for the part of
     the RESEARCH COLLABORATION to be undertaken by CAT.

3.14 Conduct of the RESEARCH COLLABORATION  Each party shall carry out its part
     -------------------------------------
     of the RESEARCH COLLABORATION as allocated to them by JRC:

     (a)  with all due diligence and so as to meet key milestone dates set out
          in the RESEARCH PROTOCOL;

     (b)  in accordance with GLP (where applicable), GCP and GMP and all other
          relevant legal requirements and shall be responsible for obtaining all
          necessary approvals therefor from any COMPETENT AUTHORITY; and

     (c)  keeping or causing to be kept detailed written and appropriately
          witnessed laboratory notebooks and other records and reports of the
          progress of its part of the RESEARCH COLLABORATION in sufficient
          detail and in good scientific manner for all purposes, including
          patent purposes.  Such notebooks and other records must properly
          reflect all work done on the RESEARCH COLL"BORATION and the results
          achieved thereunder.

3.15 Subcontracting  Neither party shall sub-contract the whole or any part of
     --------------
     its portion of the RESEARCH COLLABORATION without the consent of JRC.  If
     such consent is given, the appointment of any sub-contractor shall be on
     the following terms:

                                       21
<PAGE>

     (a)  that SEARLE shall pay the funds identified for the work required from
          the sub-contractor;

     (b)  that as among the parties and the sub-contractor all results emerging
          from such work and any related intellectual property, including
          INVENTIONS, shall be owned by SEARLE;

     (c)  that the sub-contractor shall be obligated on terms the same as
          Article 8 (Confidentiality) of this Agreement.

3.16 Reports  Each party ("Reporting Party") shall within twenty-one (21) days
     -------
     of the end of each COLLABORATION YEAR quarter send a written report to the
     other party and to its Members on JRC, which shall summarize in reasonable
     detail the progress achieved and results obtained by the Reporting Party
     and its sub-contractors pursuant to the RESEARCH COLLABORATION during such
     quarter.

     ARTICLE 4 - INVESTMENT, MILESTONE AND ROYALTY PAYMENTS

4.1  Equity Investment in CAT GROUP  SEARLE shall agree to purchase an amount of
     ------------------------------
     the issued ordinary share capital of CAT GROUP costing not more than twelve
     million five hundred thousand dollars (US$12,500,000), pursuant to the
     SUBSCRIPTION AGREEMENT.

4.2  Ongoing Information After The EFFECTIVE DATE  SEARLE shall be entitled to
     --------------------------------------------
     and CAT shall provide to SEARLE not later than thirty (30) days after the
     end of each calendar quarter a report covering the following areas:

     [***]

     However SEARLE shall not be entitled to receive details of internal CAT
     programs or third party programs or any confidential information which CAT
     is contractually precluded from sharing with a third party.

     In addition, from time to time upon reasonable written notice SEARLE shall
     also have the right to address the Board of CAT at any of its regularly
     scheduled meetings about any matters of material concern to SEARLE.  Such
     right of address may be in writing or by physical attendance of a SEARLE
     nominee at SEARLE's option.

     For six (6) months after the EFFECTIVE DATE CAT and SEARLE will jointly
     seek to identify an individual acceptable to SEARLE and to the Board of CAT
     as a suitable non-executive director of CAT and CAT GROUP PLC.  If no
     suitable candidate is identified within six (6) months from the EFFECTIVE
     DATE then this provision shall lapse.

                                       22
<PAGE>

4.3  Technical Performance Milestones  For each TARGET which is included in the
     --------------------------------
     RESEARCH COLLABORATION pursuant to the terms hereof, SEARLE shall pay the
     following Technical Performance Milestones:

     Milestone                                            Amount
     ---------                                            ------

     (i)    [***]                                        [***]

     (ii)   [***]                                        [***]

     (iii)  [***]                                        [***]

4.4  Use of CAT Technology on Exclusive TARGET  Subject to payment of any
     -----------------------------------------
     applicable such Technical Performance Milestone, CAT hereby grants SEARLE
     permanent, exclusive rights to use any and all CAT KNOW HOW and MATERIALS
     (a) to elucidate the nature, SAR or conformation of the TARGET or any
     mechanism of action related to the TARGET and (b) to identify, to develop
     or to enhance any direct or indirect approach to modulate such TARGET and
     provided that SEARLE is maintaining an active development program relating
     to a LICENSED PRODUCT relating to the TARGET.
4.5  Annual Caps  Should SEARLE pay for Technical Performance Milestones
     -----------
     aggregating to [***] in one (1) COLLABORATION YEAR, SEARLE shall not be
     obligated to pay any further Technical Performance Milestones in such year,
     provided that the foregoing aggregate payment cap shall not apply to CAT
     TARGETS if CAT has demonstrated utility with respect to such CAT TARGET in
     the manner and with the effect described in Section 4.3(i), (ii), and
     (iii).  In addition to such total cap on Technical Performance Milestone
     payments, the following additional caps shall apply in no COLLABORATION
     YEAR shall SEARLE be obligated to pay more than [***] in aggregate payments
     under Section 4.3(i) or more than [***] in aggregate payments under Section
     4.3(ii).

4.6  Development Milestone Payments  The following Development Milestone
     ------------------------------
     payments shall be payable within sixty (60) days from the date that any
     Licensed Product constituting an ANTIBODY BASED DRUG progresses through the
     applicable development phase listed below:

     [***]          upon initiation of Phase I testing
     [***]          upon initiation of Phase II testing
     [***]          upon initiation of Phase III testing
     [***]          upon first BLA filing in any MAJOR MARKET
     [***]          upon first grant of MARKETING AUTHORIZATION in any MAJOR
                    MARKETING
     [***]          upon second grant of MARKETING AUTHORIZATION in any
                    MAJOR MARKET

                                       23
<PAGE>

     The following Development Milestone payments shall be payable within sixty
     (60) days from the date that any LICENSED PRODUCT constituting a DIAGNOSTIC
     PRODUCT progresses through the applicable development phase listed below:

     [***]          upon first BLA filing in any MAJOR MARKET
     [***]          upon first grant of MARKETING AUTHORIZATION in any
                    MAJOR MARKET

     The Technical Performance Milestone and Development Milestone payments
     shall be exhaustive for the TARGET to which such LICENSED PRODUCT relates.
     No additional milestone payments shall be payable for any subsequent BLA
     filings or approvals in any country (whether or not constituting a MAJOR
     MARKET) or for new or additional indications, formulations, dosing regimens
     or changes or additions to the indications or uses of any LICENSED PRODUCT
     against any TARGET for which milestone payments have been made.  No
     additional Technical Performance Milestone or Development Milestone
     payments shall be payable for any back-up or second or later generation
     product for any particular TARGET for which prior Technical Performance
     Milestone payments and Development Milestone have been made.  Second or
     successive generation products shall be deemed to include any ANTIBODY
     BASED DRUG.  SYNTHETIC DRUG or DIAGNOSTIC PRODUCT designed for the same
     TARGET, regardless of the mechanism of action for such product.  For
     COMBINATION PRODUCTS no additional milestone payments shall be payable for
     additional LICENSED PRODUCTS used in the combination, unless such
     additional LICENSED PRODUCTS are separately registered and developed as
     stand alone pharmaceutical products with respect to another TARGET whereby
     milestones would otherwise be payable.  No milestones shall be payable for
     COMBINATION PRODUCTS incorporating two or more drugs for which milestones
     have already been paid, or in which a drug upon which milestones have been
     paid is combined with drugs which are not subject to milestone obligations
     under this AGREEMENT.

     Notwithstanding the foregoing if SEARLE elects to pursue more than one BLA
     with respect to a TARGET within the meaning of Section 1.65(iii), SEARLE
     shall only be required to pay one set of Development Milestone payments for
     such TARGET as such LICENSED PRODUCTS progress through the applicable
     development phase, unless and until such time as SEARLE is granted two (2)
     MARKETING AUTHORISATIONS under two (2) separate BLA's in any applicable
     single country.  Within [***] of such grants as described in the foregoing
     sentence, SEARLE will pay CAT all applicable Development Milestone payments
     for such additional BLA.

4.7  Royalties on ANTIBODY BASED DRUGS  During the term specified in Section
     ---------------------------------
     4.10, SEARLE will pay to CAT a royalty of

                                       24
<PAGE>

(a)  [***] of NET SALES of LICENSED PRODUCTS constituting ANTIBODY BASED
     DRUGS [***] per MARKETING YEAR; and

(b)  [***] of NET SALES of LICENSED PRODUCTS constituting ANTIBODY BASED
     DRUGS [***] per MARKETING YEAR;

(c)  [***] of NET SALES of LICENSED PRODUCTS constituting ANTIBODY BASED
     DRUGS [***] per MARKETING YEAR; and

(d)  To the extent that the royalty payable from CAT to MRC lapses or is
     voluntarily forgiven for no material consideration from CAT, the foregoing
     royalties payable from Searle to CAT in each of items (a) through (c) above
     shall be reduced by [***] of the amount of royalty from CAT to MRC which is
     lapsed or forgiven.  In the case where a product is only a LICENSED PRODUCT
     by virtue of the fact that it is a product which would otherwise give rise
     to a royalty obligation from CAT to the MRC under the license agreement
     dated 7 January 1997 as the terms exist under the license agreement as of
     the EFFECTIVE DATE the royalty payable by SEARLE to  CAT shall be reduced
     to the level of CAT's royalty obligation to the MRC

(e)  Notwithstanding the foregoing, SEARLE shall also pay CAT a royalty of [***]
     with respect to any LICENSED PRODUCT relating to the TARGET [***], for so
     long as such royalty is required to be paid by CAT to its licensor
     Progenitory (or its successor in title) pursuant to the current terms of
     CAT and Progenitor's pre-existing agreement.

(f)  CAT agrees to provide SEARLE with all reasonable assistance to negotiate a
     lump sum payment of the royalty referred to in (e) above, provided that CAT
     shall have no obligation to pay such lump sum or any other sums in
     connection with any agreement.

(g)  CAT agrees that it will pay all royalties due to MRC and Progenitor (or its
     successor in title) as referred to in (d) and (e) above, and shall in the
     event of any claim of default in that regard notify SEARLE in writing and
     assist SEARLE to make any such payments directly to the licensors prior to
     the forfeiture or loss of the related CAT BACKGROUND IP or contract rights
     under such licenses.

4.8  Royalties on SYNTHETIC DRUGS  During the term specified in Section 4.10,
     ----------------------------
     SEARLE will pay to CAT a royalty of [***] of NET SALES of LICENSED PRODUCTS
     constituting SYNTHETIC DRUGS which have been developed as a substantial and
     direct result of the use of CAT BACKGROUND IP, [***] in total royalty
     payments over the commercial life of each such SYNTHETIC DRUG.  Following
     payment of the capped amount as provided in the foregoing sentence, SEARLE
     shall have a fully paid up, irrevocable license under this AGREEMENT with
     respect to such SYNTHETIC DRUG.

                                       25
<PAGE>

4.9  Royalties on DIAGNOSTIC LICENSED PRODUCTS  During the term specified in
     -----------------------------------------
     Section 4.10, SEARLE will pay to CAT a royalty on NET SALES of LICENSED
     PRODUCTS constituting DIAGNOSTIC PRODUCTS equal to the amount of CAT's
     obligations to pay royalties to third parties (including but not limited to
     MRC) in respect of sales of such DIAGNOSTIC PRODUCTS subject to clause
     4.7(d).

4.10 Calculation and Payment  Royalties shall be calculated on a quarterly
     -----------------------
     basis and payable within sixty (60) days after the end of each calendar
     quarter based upon NET SALES of LICENSED PRODUCT during the previous
     calendar quarter.  All royalties payable under this AGREEMENT shall be
     paid, on a country-by-country basis, from the date of FIRST COMMERCIAL SALE
     of each LICENSED PRODUCT in a particular country until the later of (i) the
     last to expire in any such country of any valid and enforceable CAT
     BACKGROUND PATENT RIGHT which covers the manufacture, use or sale of such
     LICENSED PRODUCT in such country or (ii) [***] from FIRST COMMERCIAL SALE
     in such country (or in the case of the United States) [***] only.

     Upon the expiration of the royalty payment period for a LICENSED PRODUCT in
     a country described above, SEARLE shall thereafter have an irrevocable,
     exclusive, sublicensable, paid up license to make, have made, use, sell,
     offer for sale, have sold and import such LICENSED PRODUCT in that country.

4.11 Reports  SEARLE shall furnish to CAT on a six monthly basis a written
     -------
     report of the NET SALES, on a product by product basis, of all LICENSED
     PRODUCTS by SEARLE and its AFFILIATES on a worldwide basis, for the
     calendar quarter upon which the royalty payment is based.  Any royalty due
     CAT for such calendar quarter shall be paid by SEARLE when submitting such
     reports.

4.12 Records  SEARLE shall keep full, complete, and proper records and accounts
     -------
     of NET SALES of LICENSED PRODUCT in sufficient detail to enable the
     royalties payable by SEARLE to CAT to be determined.  CAT shall have the
     right at its own expense, upon reasonable written notice to SEARLE, to
     retain an independent certified public accountant acceptable to SEARLE to
     audit SEARLE's records pertaining to such LICENSED PRODUCT for the purpose
     of verifying the accuracy of the payment of royalties to CAT under this
     AGREEMENT for the three (3) preceding years, but this right may not be
     exercised more than once in any year.  The accountant shall disclose to CAT
     only made according to this AGREEMENT.  In the event of any underpayment,
     SEARLE shall promptly remit to CAT all amounts due.  In the event of any
     overpayment, CAT shall promptly remit to SEARLE all amounts overpaid to
     CAT.

4.13 Exchange of Currency  The remittance of royalties payable on NET SALES of
     --------------------
     LICENSED PRODUCT for sales in currencies other than United States dollars
     shall be payable to CAT in such dollars calculated using the appropriate
     exchange rate for such

                                       26
<PAGE>

     currency quoted in The Wall Street Journal (Midwest Edition) on the last
     Business Day of the calendar quarter for which the royalties accrue.

4.14 Withholding Taxes  Any tax which SEARLE is required to pay or withhold
     -----------------
     with respect of the payments to be made to CAT hereunder shall be deducted
     from the amount otherwise due provided that, in regard to any such
     deduction, SEARLE shall give CAT such assistance, which shall include the
     provision of such documentation as may be required by any revenue authority
     and other revenue services, as may reasonably be necessary to enable CAT to
     claim exemption therefrom or obtain a repayment thereof or a reduction
     thereof and shall upon request provide such additional documentation from
     time to time as is needed to confirm the payment of tax.

4.15 Bank Account  All payments made to CAT under this AGREEMENT shall be made
     ------------
     by wire transfer to the bank account of CAT in the United Kingdom to
     Barclays Bank PLC Cambridge Business Centre PO Box 326, Cambridge CB4 3UT;
     sort code number 20-17-19; account number 90192325 or such other bank
     account in the United Kingdom as is notified by CAT in writing to SEARLE
     from time to time.

4.16 Late Payment  If either party fails to make any payment due hereunder on
     ------------
     the due date for payment, without prejudice to any other right or remedy
     available to the other party it shall be entitled to charge interest (both
     before and after judgment) on the amount unpaid at the rate of LIBOR plus
     4% calculated on a daily basis until payment in full is made without
     prejudice to a party's right to receive payment on the due date.
                            ARTICLE 5 - CAT TARGETS

5.1  SUBTRACTED COMPLEMENTARY cDNAs and PLASMIDS
     -------------------------------------------

     (a)  As soon as practicable after the EFFECTIVE DATE, CAT shall release to
          SEARLE at CAT's principal research facilities, at no cost to SEARLE,
          cDNA sets associated with [***] of the CAT SUBTRACTED LIBRARIES as
          shall be determined by the JRC.  SEARLE shall, at its own cost and
          expense, within [***] of receipt of such cDNA sets sequence such cDNA
          sets to a minimum depth of [***].  Any and all MATERIALS, KNOW HOW,
          DOCUMENTS, data and other information which directly results from such
          initial sequencing by SEARLE, shall be owned by CAT and shall be
          provided by SEARLE to CAT on a regular, but not less than monthly,
          basis; provided that CAT's ownership of such rights is subject to
          SEARLE's rights to treat any TARGETS as SEARLE TARGETS or to secure
          royalties as provided below.

     (b)  Provided that CAT releases the cDNA sets to a SEARLE representative at
          the site designated above, SEARLE will (i) process the cDNA sets into
          arrays and use them to construct cDNA microarrays and generate initial
          sequence data and (ii) make a payment of [***] to CAT.  If such
          payment is made, then consistent [***],

                                       27
<PAGE>

          CAT will undertake to support SEARLE research activities under the
          RESEARCH PROTOCOL during the initial COLLABORATION YEAR, with a
          commitment of no less than [***] FTEs, for the nominal sum of [***].

5.2  SEARLE's Option  For a period of six (6) months from the EFFECTIVE DATE CAT
     ---------------
hereby grants to SEARLE an option to sequence any or all of the CAT SUBTRACTED
LIBRARIES not selected by JRC under Section 5.1 such option to be exercisable
merely upon notice to CAT given at any time during the term of this AGREEMENT.
If SEARLE exercises the option granted under this Section 5.2 then this Article
5 shall apply to SEARLE's sequencing of the CAT SUBTRACTED LIBRARIES in respect
of which SEARLE exercises this option.

5.3  Exclusivity  SEARLE shall have the exclusive right for [***] from the end
     -----------
of the calendar month in which it provides to CAT data and information relating
to a CAT TARGET, to determine, in SEARLE's sole discretion, whether such CAT
TARGET should be proposed to JRC for inclusion in the RESEARCH PROTOCOL and if
it so determines, then SEARLE shall propose within such period, such CAT TARGET
to the JRC and the provisions of Article 6 shall apply.

5.4  CAT's Rights and Obligations in Respect of a CAT SEQUENCE  During the [***]
     ---------------------------------------------------------
period of exclusivity under Section 5.3, CAT may not grant any licenses to, or
enter into any collaboration with, any third party in respect of such CAT
TARGET.  If at the end of such [***] period or thereafter (i) SEARLE determines
not to propose such CAT TARGET to JRC for inclusion in the RESEARCH PROTOCOL or
(ii) JRC does not accept such proposal or (iii) having accepted such proposal
the relevant RESEARCH PROTOCOL is thereafter discontinued or terminated for any
reason (other than CAT's default under this AGREEMENT or completion of such
PROTOCAL) then CAT shall be free to grant any licenses to third parties or carry
out research on its own behalf or otherwise deal in any way it deems fit in
respect of such CAT TARGET.

5.5  SEARLE's Step-back Rights  Where any CAT TARGET is included in the RESEARCH
     -------------------------
COLLABORATION and where a RESEARCH PROGRAM in respect of such CAT TARGET is
subsequently discontinued or terminated for any reason, SEARLE may, up to and
including thirty (30) BUSINESS DAYS after the point where CAT has demonstrated
the utility of the CAT TARGET in an animal model of disease, elect to propose
such CAT TARGET to the JRC for inclusion in the RESEARCH COLLABORATION and the
provisions of Article 6 shall apply.  If the JRC accepts such proposal such CAT
TARGET shall become the subject of a RESEARCH PROTOCOL provided that

(a)  SEARLE fully reimburses CAT for all expenses incurred by CAT in respect of
     such CAT TARGET (plus interest compounded annually thereon computed at
     [***] thereof after allowing for taxation at UK standard rates and payable
     in one lump sum) up to and including the demonstration of utility in an
     animal model of disease; and

                                       28
<PAGE>

(b)  SEARLE pays any and all Technical Performance Milestone payments which
     would have accrued and been payable had such CAT TARGET been proposed by
     SEARLE and accepted for inclusion in the RESEARCH COLLABORATION within the
     [***] period of exclusivity under Section 5.3.

     SEARLE's step-back right shall not apply if pursuant to Section 5.4. [***]

              ARTICLE 6 - RESEARCH PROTOCOLS AND TARGET SELECTION

6.1  Proposal of TARGETS
     -------------------

     (a)  SEARLE may at any time during the term of the RESEARCH COLLABORATION
          propose to the JRC that a TARGET be included in the RESEARCH
          COLLABORATION.  CAT may also at any time propose a TARGET for
          inclusion in the RESEARCH COLLABORATION

     (b)  SEARLE may propose TARGETS from the LIST or otherwise.  The LIST shall
          be limited at any point in time as described in Section 1.38.  SEARLE
          may amend the LIST from time to time upon written notice to CAT,
          subject to Section 6.2.

     (c)  A TARGET shall be deemed to be on the LIST as of the date of SEARLE=s
          written notice to CAT so listing such TARGET subject except for those
          on the LIST to the provisions of Section 6.2.

     (d)  CAT may request at any regularly scheduled meeting of the JRC that any
          TARGET on the Part B LIST become the subject of a RESEARCH PROGRAM or
          be removed from the PART B LIST; provided that, CAT shall make such
          request for no more than [***] such TARGETS at any one JRC meeting and
          shall make such request only in connection with a bona fide proposal
          for a collaboration with a third party or a bone fide proposal for its
          own in house activity for such TARGET.  For the purposes of this
          clause a bone fide proposal for CAT=s in house activity shall mean a
          proposal to commit resource equivalent to at least [***] FTE within
          the following [***].

     (e)  Within thirty (30) days of CAT=s request pursuant to paragraph (d)
          above, SEARLE must either delete the applicable TARGET(s) or propose
          to the JRC a RESEARCH PROGRAM or PROGRAMS with respect thereto.

     (f)  A TARGET which has progressed to a RESEARCH PROGRAM shall be deemed
          deleted from the LIST and thus shall no longer count against the
          limitation of TARGETS for such LIST.

                                       29
<PAGE>

6.2  Right of Decision  The final decision as to whether a TARGET shall be
     -----------------
     included in the RESEARCH COLLABORATION shall be SEARLE's, provided that
     subject to the other terms and conditions of this AGREEMENT (including
     those with respect to TARGETS such as Sections 2.3 and/or 2.4), CAT shall
     have the right to reject a proposed TARGET for a RESEARCH PROGRAM or the
     LIST other than those on the original LIST within [***] of the date of the
     said proposal if:

     [***]

6.3  INDEPENDENT COUNSEL
     -------------------

     (a)  In order to provide a method of resolving disputes as to the
          availability of, and exclusivity with respect to, a TARGET for
          activities pursuant to the RESEARCH COLLABORATION while preserving
          confidentiality of TARGET selection by CAT and third parties, the
          parties have appointed an INDEPENDENT COUNSEL.

     (b)  The INDEPENDENT COUNSEL shall not be an agent of either party, but
          instead act as referee solely for the purpose described above.

     (c)  The parties may remove the INDEPENDENT COUNSEL and appoint a new
          INDEPENDENT COUNSEL if the parties so agree in writing or if the
          INDEPENDENT COUNSEL violates the decision-making parameters as stated
          in this AGREEMENT or the separate agreement among CAT, SEARLE and each
          INDEPENDENT COUNSEL to be entered into at the time of (or no later
          than thirty (30) days from) the appointment of such counsel by the
          parties.
     (d)  Such separate agreement shall provide among other things that

          (i)    the INDEPENDENT COUNSEL will return to the applicable
          depositor, one year following the end of the RESEARCH COLLABORATION
          (or, if earlier, within fifteen (15) BUSINESS DAYS of such counsel
          ceasing to be the INDEPENDENT COUNSEL hereunder) all materials
          required under this AGREEMENT to be submitted to the INDEPENDENT
          COUNSEL;

          (ii)   the INDEPENDENT COUNSEL shall charge for its services by the
          TARGET in dispute at such counsel's regular hourly rates, and SEARLE
          shall pay such charges if the INDEPENDENT COUNSEL determines that the
          TARGET may not be included in a RESEARCH PROGRAM, and CAT shall pay
          such charges if the INDEPENDENT COUNSEL determines that the TARGET may
          be included in a RESEARCH PROGRAM;

          (iii)  the INDEPENDENT COUNSEL shall maintain all information
          deposited with it in confidence and other than disclosing to the
          parties that a TARGET may

                                       30
<PAGE>

          or may not be included in a RESEARCH PROGRAM, shall not disclose
          either party's confidential information to the other party; and

          (iv)   the INDEPENDENT COUNSEL will, however, permit from time to
          time an independent patent counsel nominated by a party and as to whom
          the other party has no reasonable objection, to examine the documents
          and notes of the INDEPENDENT COUNSEL with respect to such INDEPENDENT
          COUNSEL's determination as to one or more TARGETS.

                        ARTICLE 7 - TARGET EXCLUSIVITY

7.1  TARGET Exclusivity  CAT and SEARLE shall exclusively deal with each other
     ------------------
in respect of human antibody research and development directed to a TARGET (i)
if during the RESEARCH COLLABORATION the TARGET is on the LIST, (ii) if the
TARGET is the subject of a RESEARCH PROGRAM, or (iii) at such other point as the
parties may determine.  If at the conclusion of a RESEARCH PROGRAM SEARLE
determines that it will continue to develop a LICENSED PRODUCT which is an
ANTIBODY BASED DRUG relating to a TARGET than it shall notify CAT and the
parties shall remain exclusive to each other in respect of that TARGET until the
earlier of [***] from the filing of an IND or its equivalent in a MAJOR MARKET
or until SEARLE notifies CAT that it or its sub-licensee is ceasing to develop
such LICENSED PRODUCT relating to that TARGET.  IF SEARLE or a sub-licensee
determines that it will not develop such LICENSED PRODUCT relating to a TARGET
pursuant to this Section then SEARLE shall notify CAT promptly and SEARLE=s
license pursuant to Section 2.1(b) only with respect to the abandoned LICENSED
PRODUCT as described above shall cease with immediate effect.

7.2  Meaning of Exclusively  For the purposes of Section 7.1 "exclusively" shall
     ----------------------
mean for all indications and uses (a) that CAT may not conduct any research
either on its own behalf or with a third party in respect of the relevant TARGET
and (b) that SEARLE shall not conduct any research either on its own behalf or
with a third party in respect of human antibodies in development as therapeutics
for that TARGET.

7.3  Effect of Termination of Exclusivity  If for any reason the JRC determines
     ------------------------------------
to terminate the RESEARCH PROGRAM in respect of a TARGET prior to completion of
such RESEARCH PROGRAM as noted in minutes prepared under Section 3.12(c), then
the mutual exclusivity between the parties in respect of that TARGET shall
terminate [***] after the date such determination is noted in the minutes.

                   ARTICLE 8 - CONFIDENTIALITY AND PUBLICITY

8.1  Confidentiality  Disclosures of confidential and proprietary information
     ---------------
hereunder made by either party to the other shall be made in writing (or
promptly confirmed in writing if made in another form), and shall be marked
"Confidential." Such confidential information shall be

                                       31
<PAGE>

safeguarded by the recipient in the same manner and to the same extent that it
safeguards its own confidential information and materials, and shall not be
disclosed to third parties (other than each party's financial and legal
advisors, each of whom shall be bound by confidentiality obligations identical
to those contained herein, whether express or implied), except as otherwise
expressly permitted in this AGREEMENT or permitted in writing by the disclosing
party. Each party agrees to only use such confidential information for the
purposes contemplated in this AGREEMENT. These mutual obligations of
confidentiality shall apply for a period of ten (10) years after the termination
of this AGREEMENT, but such obligations shall not apply to any information that:

(a)  is available to the public at the time it is disclosed;

(b)  becomes available to the public without a breach of
     this AGREEMENT by the recipient of such confidential information;

(c)  recipient already possesses at the time it is disclosed as evidenced by
     written documentation;

(d)  is internally developed by recipient independently of and wholly without
     knowledge of the disclosing party's confidential information as evidenced
     by written documentation;

(e)  is required to be disclosed by SEARLE in order to manufacture, have
     manufactured, market or sell a LICENSED PRODUCT; or

(f)  is otherwise required to be disclosed in compliance with applicable laws or
     regulations or order by a court or other regulatory body having competent
     jurisdiction.

8.2  Publicity  Neither party shall use the name of the other party or any of
     ---------
its employees in any advertising, promotional, or sale literature without the
prior written consent of the other party, such consent not to be unreasonably
withheld.  A party may, however, disclose the existence of this AGREEMENT.
SEARLE shall not use the name of CAT or any of CAT's trademarks in connection
with the use or sale of LICENSED PRODUCT by SEARLE or any advertising,
promotional, or sales literature, without the prior consent of CAT.  CAT shall
not publish any documents containing references to SEARLE BACKGROUND IP or
RESEARCH COLLABORATION IP absent SEARLE's prior written consent.

                     ARTICLE 9 - PATENTS AND INFRINGEMENT

9.1  Intellectual Property Ownership  Any and all RESEARCH COLLABORATION IP
     -------------------------------
discovered or developed incident to the performance of this Agreement shall be
owned by SEARLE irrespective of which party invents or discovers such RESEARCH
COLLABORATION IP (including SEARLE IMPROVEMENT IP), except that notwithstanding
any provision of this AGREEMENT which might otherwise be to the contrary, CAT
shall own

                                       32
<PAGE>

all CAT IMPROVEMENT IP. SEARLE shall grant CAT a permanent, non-exclusive,
royalty-free license, without rights to sub-license, to such RESEARCH
COLLABORATION IP, solely for CAT's own internal research efforts and for no
other or further purpose.

CAT hereby agrees to assign any such RESEARCH COLLABORATION IP to SEARLE. Upon
the request of SEARLE, CAT will have its employees and any permitted consultants
promptly execute any and all applications, assignments or other instruments
which SEARLE shall deem necessary or useful in order for SEARLE to apply for and
obtain patent protection worldwide for said RESEARCH COLLABORATION IP and in
order to assign and convey to SEARLE the sole and exclusive right, title, and
interest in and to said RESEARCH COLLABORATION IP and patent applications and
patents thereon. All expenses incurred incident to such filings shall be for
SEARLE's account. CAT shall require all employees and any permitted consultants
to sign and maintain such employment and consultancy agreements as (a) will
preserve the patentability of all INVENTIONS, whether patentable or otherwise,
arising from the performance of research for SEARLE by CAT for the benefit of
SEARLE and (b) will provide for the unrestricted free assignment of all claims
of inventorship or ownership of any PATENT RIGHTS to SEARLE, without retention
of shop rights or other residual rights of practice of such inventions.

9.2  CAT BACKGROUND IP CAT shall at its own cost and expense be solely
     -----------------
responsible for the filing, prosecution and maintenance of CAT BACKGROUND IP,
using reasonable endeavors to prosecute all patent applications forming part of
CAT BACKGROUND IP including the conduct of any claims or proceedings relating to
them including any interference or opposition proceedings. CAT shall keep SEARLE
informed of all material developments in relation to CAT BACKGROUND IP, in each
case so far as they relate to any LICENSED PRODUCT.

9.3  SEARLE BACKGROUND IP and RESEARCH COLLABORATION IP SEARLE shall at its own
     --------------------------------------------------
cost and expense be solely responsible for the filing, prosecution and
maintenance of SEARLE BACKGROUND IP and RESEARCH PROGRAM IP, using reasonable
endeavors to prosecute all patent applications forming part of SEARLE BACKGROUND
IP AND RESEARCH PROGRAM IP including the conduct of any claims or proceedings
relating to them including any interference or opposition proceedings. SEARLE
shall keep CAT informed of all material developments in relation to SEARLE
BACKGROUND IP and RESEARCH PROGRAM IP, in each case so far as they relate to any
LICENSED PRODUCT.

9.4  Notice of Third Party Infringement CAT and SEARLE shall each give the
     ----------------------------------
other immediate written notice of any infringement or threatened infringement or
misappropriation of the CAT BACKGROUND IP, the SEARLE BACKGROUND IP and the
RESEARCH COLLABORATION IP which comes to their attention during the term of this
AGREEMENT.

9.5  Third Party Infringement CAT may, but shall not be obliged to, at its own
     ------------------------
cost and expense, enforce the CAT BACKGROUND IP against infringers. Prior to
the commencement of

                                       33
<PAGE>

proceedings, CAT shall have sole conduct of the dispute. Where it is necessary
for CAT to commence proceedings as plaintiff which directly relate to any
LICENSED PRODUCT only it shall be entitled to join SEARLE as co-plaintiff and as
co-plaintiff SEARLE shall provide all reasonable assistance in relation to such
proceedings at CAT's own cost and expense. At the written request of SEARLE, it
shall be entitled to be separately represented in such circumstances at its own
cost and expense. If SEARLE is not so separately represented, CAT shall have
sole conduct of such proceedings, including the right to settle them. In
circumstances where SEARLE is not separately represented, if CAT succeeds in any
proceedings whether at trial or by way of settlement, CAT shall be entitled to
any such award. If SEARLE is separately represented, the parties shall each
retain any award or settlement of costs and damages made in their favor. If CAT
fails to take or diligently pursue any such proceedings which directly relate to
a LICENSED PRODUCT within ninety (90) days of receiving notice on infringement,
SEARLE may give CAT thirty (30) days notice requiring CAT to take such
proceedings within thirty (30) days of the date of the notice. If CAT fails to
do so and subject to the rights of the MRC as set out in the CAT/MRC Agreement
of January 7 1999, SEARLE may be entitled to do so at its own cost and expense.
If it does CAT shall provide all necessary assistance to SEARLE in relation to
such proceedings at SEARLE's cost and expense. CAT shall not be entitled to be
separately represented in such circumstances and SEARLE shall have sole conduct
of such proceedings including the right to settle them. If Searle succeeds in
any such proceedings [***].

SEARLE may, but shall not be obliged to, at its own cost and expense, enforce
the SEARLE BACKGROUND IP and RESEARCH PROGRAM IP against infringers. Prior to
the commencement of proceedings, SEARLE shall have sole conduct of the dispute.

Where it is necessary for SEARLE to commence proceedings as plaintiff relating
to any LICENSED PRODUCT only, it shall be entitled to join CAT as co-plaintiff
and CAT as co-plaintiff shall provide all reasonable assistance in relation to
such proceedings at SEARLE's cost and expense. At the written expense of CAT, it
shall be entitled to be separately represented in such circumstances at its own
cost and expense. If CAT is not so separately represented, SEARLE shall have
sole conduct of such proceedings, including the right to settle them unless
otherwise agreed by the parties. In circumstances where CAT is not separately
represented if SEARLE succeeds in any proceedings whether at trial or by way of
settlement, SEARLE shall be entitled to retain any such award. If CAT is
separately represented, the parties shall each retain any award or settlement of
costs and damages made in their favor. If SEARLE fails to take or diligently
pursue any such proceedings within ninety (90) days of receiving notice of
infringement, CAT may give SEARLE thirty (30) days notice requiring SEARLE to
take such proceedings within thirty (30) days of the date of the notice and if
SEARLE fails to do so CAT shall be entitled to do so at its own cost and expense
and SEARLE shall provide all necessary assistance to CAT in relation to such
proceedings at CAT's cost and expense. SEARLE shall not be entitled to be
separately represented in such circumstances and CAT shall have sole conduct of
such proceedings including the right to settle them. If CAT succeeds in any such
proceedings, [***].

                                       34
<PAGE>

9.6   Infringement of Third Party Patent Rights If during the period of this
      -----------------------------------------
AGREEMENT either party receives any notice, claim or proceedings from any third
party alleging infringement of that third party's intellectual property by
reason of any party's activities in relation to this AGREEMENT, the party
receiving that notice shall:

(a)   forthwith notify the other party of the notice, claim or proceeding; and

(b)   neither party shall make any admission of liability.

Each party shall control its own defense in any such patent litigation. Neither
party will object to the intervention of the other party in any such litigation
and, to the extent that their interests are consistent, each will cooperate and
provide reasonable assistance to the other with respect of such litigation. Each
party shall pay its own costs and expenses of defense of such suit.

                  ARTICLE 10 - REPRESENTATIONS AND WARRANTIES

10.1  Authority Both CAT and SEARLE warrant to the other party that they each
      ---------
have full right, power, and authority to enter into this AGREEMENT and the
execution and performance of this AGREEMENT shall not knowingly constitute a
violation of any material covenant or restriction or a breach of any obligation
under any other agreement, contract, commitment, rule or regulation to which CAT
or SEARLE is a party or by which CAT or SEARLE is bound.

10.2  Patent Infringement Warranty CAT warrants to SEARLE that it is presently
      ----------------------------
aware of no patents or patent applications owned by a third party which would
present any issue of infringement by reason of the performance of this AGREEMENT
by CAT or SEARLE as it relates to the CAT CORE TECHNOLOGY or its use as
contemplated under this Agreement including the identification of LICENSED
PRODUCT.

10.3  Warranty of Non-Dominance CAT further warrants to SEARLE that it owns no,
      -------------------------
and is aware of no, patents, patent rights or patent applications or other
intellectual property rights or claims dominant to the CAT BACKGROUND IP.  CAT
further warrants that CAT has provided SEARLE with all written opinions (formal
and informal) which bear on the practice of any rights granted to SEARLE in this
AGREEMENT, as they relate to the CAT BACKGROUND IP including without limitation
all opinions on patentability, validity or infringement.

10.4  Capacity and Rights CAT further warrants to SEARLE that CAT has all
      -------------------
necessary rights and tracking and reporting systems to conduct the work required
under the RESEARCH PROTOCOL in compliance with this AGREEMENT and in an
auditable manner.

10.5  Warranty Against Unauthorized Use of CAT BACKGROUND IP SEARLE warrants to
      ------------------------------------------------------
CAT that SEARLE shall not license, authorize or enable third parties performing
research on SEARLE's behalf to use or make any claim of ownership or right to
use CAT BACKGROUND

                                       35
<PAGE>

IP other than for the purposes of performance of IN-HOUSE RESEARCH in accordance
with Section 2.1(a).

10.6  Disclaimer of Statutory or Implied Warranties EXCEPT AS OTHERWISE
      ---------------------------------------------
EXPRESSLY SET FORTH IN THIS ARTICLE, NEITHER CAT NOR SEARLE MAKES ANY
REPRESENTATIONS AND EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OR MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE. ALL UNIFORM COMMERCIAL CODE OR OTHER STATUTORY WARRANTIES
ARE HEREBY EXPRESSLY DISCLAIMED.

                  ARTICLE 11 - LIABILITY AND INDEMNIFICATION

11.1  Indemnification of CAT by SEARLE SEARLE shall indemnify, defend and hold
      --------------------------------
harmless CAT and its affiliates and subcontractors, and their respective
stockholders, directors, officers, employees, and agents and their respective
successors, heirs and assigns (the "CAT Indemnitees"), against any liability,
                                    ---------------
damage, loss, settlement, cost or expense (including reasonable attorneys' fees
and expenses of litigation) ("Losses") incurred by or imposed upon the CAT
                              ------
Indemnitees, or any one of them, in connection with any claims, suits, actions,
administrative proceedings, demands or judgments of third parties ("Claims"),
                                                                    ------
including without limitation personal injury and product liability matters
(except in cases where such Claims result from a material breach of this
AGREEMENT or negligence or willful misconduct on the part of CAT or from or
relating to any actions taken by or on behalf of CAT with respect to CAT
BACKGROUND IP, or a defect in or infringement by practice of such CAT BACKGROUND
IP), arising out of or related to (a) any actions of SEARLE and its directors,
officers, employees and agents and their respective successors, heirs and
assigns in the performance of the RESEARCH PROTOCOL, (b) the production,
manufacture, promotion, sale or use by any person of any LICENSED PRODUCT which
is manufactured or sold by SEARLE or by an Affiliate, sublicensee, distributor
or agent of SEARLE (other than CAT or any Affiliate of CAT's), (c) SEARLE
BACKGROUND IP provided by SEARLE to CAT in connection with the RESEARCH
PROTOCOL, or (d) the breach by SEARLE of any provision of this AGREEMENT.

11.2  Indemnification of SEARLE by CAT CAT shall indemnify, defend and hold
      --------------------------------
harmless SEARLE and its affiliates and subcontractors, and their respective
stockholders, directors, officers, employees, and agents and their respective
successors, heirs and assigns (the "SEARLE Indemnitees"), against any Losses
                                    ------------------
incurred by or imposed upon the SEARLE Indemnitees, or any one of them, in
connection with any Claims, including without limitation claims of suppliers and
CAT employees in the case of clause (a) below and personal injury and product
liability matters in the case of clause (b) below (except in cases where such
Claims result from a material breach of this AGREEMENT or negligence or willful
misconduct on the part of SEARLE or from or relating to any actions taken by or
on behalf of SEARLE with respect to SEARLE BACKGROUND IP, or a defect in or
infringement by practice by such SEARLE

                                       36
<PAGE>

BACKGROUND IP), arising out of or related to (a) any actions of CAT and its
directors, officers, employees and agents and their respective successors, heirs
and assigns in the performance of the Research Program, (b) CAT BACKGROUND IP,
or (c) the breach by CAT of any provision of this AGREEMENT.

11.3  Notice, Etc. Each Indemnitee agrees to give the indemnifying Party prompt
      ------------
written notice of any Claim, for which such Indemnitee intends to assert a right
to indemnification under this Agreement; provided, however, that failure to give
such notification shall not affect the Indemnitee's entitlement to
indemnification hereunder except to the extent that the indemnifying Party shall
have been prejudiced as a result of such failure. The indemnifying Party shall
have the sole right (but not the obligation) to defend, settle or otherwise
dispose of any Claim or which the Indemnitee intends to assert a right to
otherwise dispose of any Claim for which the Indemnitee intends to assert a
right to indemnification under this AGREEMENT as contemplated in the preceding
sentence on such terms as the indemnifying Party, in its sole discretion, shall
deem appropriate if and so long as the indemnifying Party has recognized in a
written notice to the Indemnitee its obligation to indemnify the Indemnitee for
any Losses relating to such Claim, and at the indemnifying party's option
(subject to the limitations set forth below) shall be entitled to appoint lead
counsel of such defense with a nationally recognized reputable counsel
acceptable to the Indemnitee; provided, that the indemnifying party shall not
have the right to assume control of such defense and shall pay the fees and
expenses of counsel retained by the Indemnitee, if the claim which the
indemnifying party seeks to assume control (i) seeks non-monetary relief, (ii)
involves criminal or quasi-criminal allegations, (iii) involves a claim to which
the Indemnitee reasonably believes an adverse determination would be detrimental
to or injure the Indemnitee's reputation or future business prospects, or (iv)
involves a claim which, upon petition by the Indemnitee, the appropriate court
rules that the indemnifying party failed or is failing to vigorously prosecute
or defend. If the indemnifying party is permitted to assume and control the
defense and elects to do so, the Indemnitee shall have the right to employ
counsel separate from counsel employed by the indemnifying party in any such
action and to participate in the defense thereof, but the fees and expenses of
such counsel employed by the Indemnitee shall be at the expense of the
Indemnitee unless (i) the employment thereof has been specifically authorized by
the indemnifying party in writing, or (ii) the indemnifying party has been
advised by counsel that a reasonable likelihood exists of a conflict of interest
between the indemnifying party and the Indemnitee. If the Indemnifying Party
shall control the defense of any such claim, the indemnifying Party shall obtain
the written consent of the Indemnitee prior to ceasing to defend, settling or
otherwise disposing of any Claim if as a result thereof the Indemnitee would
become subject to injunctive or other equitable relief that could reasonably be
expected to have a material adverse effect on the business of the Indemnitee in
any nonmonetary manner.

                 ARTICLE 12 - EFFECT OF EXPIRY AND TERMINATION

12.1  Effect of Termination of RESEARCH COLLABORATION Expiration or other
      -----------------------------------------------
termination of the RESEARCH COLLABORATION by either party shall not have the
effect of

                                       37
<PAGE>

causing the termination of this AGREEMENT which shall continue in full force and
effect until expiry or early termination in accordance with its terms.

12.2  Effect of Expiry or Termination of this AGREEMENT Upon expiration or
      -------------------------------------------------
other termination of this AGREEMENT) all licences granted by CAT to SEARLE
hereunder shall become perpetual subject to SEARLE'S obligation to pay royalties
hereunder except in the event of termination due to SEARLE's default or
bankruptcy under Sections 13.5 or 13.6. Termination of this AGREEMENT shall not
relieve either party from (i) an obligation of which performance was due prior
to the termination or of which the AGREEMENT specifies that performance was to
survive termination; or (ii) liability for a breach or for any misrepresentation
under this AGREEMENT. Notwithstanding any provisions of this Agreement which
might otherwise be to the contrary the following clauses shall survive
termination of this AGREEMENT for any reason: Articles 8, 9, 11, 14 and Sections
2.1, 2.6, 2.8, 2.9, 2.10, 3.6, 4.4, 4.7, 4.8, 4.9, 4.10, 4.11, 4.12, 4.13, 4.14,
4.15, and 4.16.

                      ARTICLE 13 - TERMS AND TERMINATION

13.1  Term The term of this AGREEMENT shall extend from the EFFECTIVE DATE
      ----
until the last to expire of all patents included in the LICENSED PATENTS.

13.2  Term of the RESEARCH COLLABORATION Except as otherwise provided herein,
      ----------------------------------
      the RESEARCH COLLABORATION shall extend for a period of three
      COLLABORATION YEARS, and thereafter for additional periods of one
      COLLABORATION YEAR each as may be extended by SEARLE under Section 13.3,
      unless otherwise terminated by SEARLE upon not less than three (3) months
      prior notice or terminated by CAT or SEARLE pursuant to Section 13.4.

13.3  Extension Terms  In the event SEARLE shall elect to extend the RESEARCH
      ---------------
      COLLABORATION as described in Section 13.3(a), FTE rates and research work
      to be performed and TARGETs to be pursued shall be redefined by the JRC
      not less than three (3) months prior to the start of the extension
      COLLABORATION YEAR. FTE rates shall be adjusted in any extension
      COLLABORATION YEAR term to reflect reasonable rates of inflation or
      deflation as reflected by actual fluctuations in salaries and expenses
      over the prior term of the RESEARCH COLLABORATION since the last
      adjustment. Research work under the RESEARCH COLLABORATION shall be
      redefined by the JRC to address the additional expertises or functions
      SEARLE may need or require from CAT which CAT then may have or could
      reasonably develop and perform during such extension on behalf of SEARLE.
      The scope and the nature of appropriate TARGETs shall be determined in
      consideration of the amount of FTE commitment SEARLE is prepared to
      pursue. The parties agree that SEARLE's commitment to FTE activities shall
      entitle SEARLE to pursue such number of TARGETS as can reasonably be
      achieved with the FTE level committed. All other TARGET exclusivity,
      milestone and royalty terms

                                       38
<PAGE>

      shall be applied to the TARGETS of the extension period, as they shall be
      applied to TARGETS in the initial term of the RESEARCH COLLABORATION.

      (a)  SEARLE may elect to extend the RESEARCH COLLABORATION by giving not
less than three (3) months advance written notice to CAT of SEARLE's intention
to extend the RESEARCH COLLABORATION and shall deliver to CAT a RESEARCH
PROTOCOL which provides work for the extension COLLABORATION YEAR which would
requires [***].

      (b)  In the event of such extension, the FTE rate shall be increased or
decreased for each COLLABORATION YEAR after the initial term by a factor of
inflation or deflation not greater than the average increase in wages and
benefits paid to researchers in Cambridgeshire, as such figure would be most
nearly approximated by government statistics published by HMSO or a similar
COMPETENT AUTHORITY.

      (c)  In the event of extension, all other terms applicable to performance
of research and rights and duties of the parties applicable in the initial term
of the RESEARCH COLLABORATION would be extended to any term of extension.

13.4  Unilateral Rights of Termination
      --------------------------------

(a)   In the event that SEARLE elects to extend the term of the RESEARCH
      COLLABORATION beyond three (3) COLLABORATION YEARS up to a full five (5)
      COLLABORATION YEARS CAT shall have the right to terminate further
      performance of the RESEARCH COLLABORATION under this AGREEMENT upon at
      least three (3) months prior written notice to SEARLE effective any time
      after the end of the fourth COLLABORATION YEAR.

(b)   In the event that CAT shall through litigation or otherwise lose exclusive
      rights to use a substantial material portion of its CAT BACKGROUND IP
      SEARLE shall have the right to terminate further performance of the
      RESEARCH COLLABORATION under this AGREEMENT upon at least six (6) months
      prior written notice to CAT, such termination to be effective upon the
      expiration of such notice period. For the purpose of this Section only CAT
      shall be deemed to have lost the use of a patent only where all applicable
      rights of appeal in any litigation, opposition proceedings, interference
      or similar judicial or quasi judicial process have been exhausted.

13.5  Termination for Breach Either party shall have the right to terminate
      ----------------------
this AGREEMENT, by notice in writing in the event that the other party is in
default or breach of any material obligation and such default or breach is not
corrected or cured within sixty (60) days after written notice thereof has been
provided by the non-defaulting or breaching party.

13.6  Insolvency Each of the parties shall have the right to terminate this
      ----------
AGREEMENT immediately upon giving written notice of termination to the other
party (the "Other Party") in

                                       39
<PAGE>

the event that any action, legal proceedings or other steps are taken by a third
party, with a view to:

     13.6.1  the winding up or dissolution of the Other Party (other than for
             solvent reconstruction); or

     13.6.2  the appointment of a liquidator, trustee, receiver or similar
             officer of the Other Party against the Other Party; or

     13.6.3  any similar or analgous step or proceedings in any country.

     and such actions, proceedings or steps are not terminated within sixty (60)
     days of commencement.

                   ARTICLE 14 - PAYMENTS, NOTICE, DELIVERIES

Any payment, notice, or other communication pursuant to this AGREEMENT shall be
sufficiently given three (3) days after the date of mailing if sent to such
party by certified first class mail, postage prepaid, addressed to it at its
address below or as it shall designate by written notice given to the other
party; or on the date of facsimile transmission (except as to payments) or hand
delivery to:

In the case of SEARLE:

                                                  Copy to:

G.D. SEARLE & Co.                       G.D. SEARLE & Co.
700 Chesterfield Parkway North          5200 Old Orchard Road
St. Louis, MO 63198                     Skokie, IL 60077
FAX: (314) 737-6987                ATTN: Associate
                                               General Counsel, Pharma
                                               Fax: (847) 581-4045

Sector
ATTN: Vice President
      of Discovery Research

In the case of CAT:

Cambridge Antibody Technology Limited
The Science Park
Melbourn
Cambridgeshire

                                       40
<PAGE>

SG8 6JJ United Kingdom
Attn: Company Secretary
44 (0)1763 263 413

                          ARTICLE 15 - MISCELLANEOUS

15.1  Assignment This AGREEMENT, with the rights and privileges it creates,
      ----------
shall not be assigned or transferred, in whole or in part, by either party
hereto without the prior written consent of the other party, provided, however,
that either party shall have the right to assign this AGREEMENT to a successor
of that party to that part of its business to which this AGREEMENT relates,
without such prior written consent of the other party.

15.2  Force Majeure Any delays in or failure of performance by either party
      -------------
under this AGREEMENT shall not be considered a breach of this AGREEMENT if and
to the extent caused by occurrences beyond the reasonable control of the party
affected, including, but not limited to: Act of God (including but not limited
to fires, floods, explosions, riots, wars, rebellions, and sabotage); acts,
regulations or laws of any government (including, without limitation, import and
export regulations); strikes or other concerted acts of workers; and lawsuits
relating to the subject matter hereof. And any time for performance hereunder
shall be extended by the actual time of delay caused by such occurrence. Each
party shall promptly give notice to the other of the starting and stopping of
the above-mentioned occurrences.

15.3  Relationship of Parties The relationship between CAT and SEARLE shall be
      -----------------------
that of independent contractors. Neither party may enter into an agreement or
assume any obligation for the other, and nothing herein should be construed as
establishing a partnership, joint venture, or principal-agent relationship
between the parties.

15.4  Waiver of Performance The waiver of any breach of any provision hereof
      ---------------------
will in no way be construed as a waiver of any succeeding breach of such
provision or a waiver of the provision itself.

15.5  Severability In the event any provision of this AGREEMENT shall be
      ------------
invalid, void, illegal, or unenforceable, the remaining provisions hereof
nevertheless will continue in full force and effect without being impaired or
invalidated.

15.6  Further Assurances: Each party hereto agrees to promptly execute and
      ------------------
deliver any document that may reasonably be requested by the other party or may
be instrumental in fulfilling the purpose of this AGREEMENT.

15.7  Law of the Contract This AGREEMENT shall be governed by and construed and
      -------------------
interpreted in accordance with the laws of the State of Illinois, United States
of America without reference to conflict of law principles.

                                       41
<PAGE>

15.8   Entire Agreement This AGREEMENT, together with the SUBSCRIPTION
       ----------------
AGREEMENT contains the entire agreement between CAT and SEARLE and supersedes
all prior agreements, whether written or oral, between the parties with respect
to the subject matter hereof. This AGREEMENT may not be amended, nor shall any
waiver, change, modification, consent, or discharge be effected except by an
instrument in writing executed by both parties.

15.9   Arbitration Any dispute related to the execution or performance of this
       -----------
AGREEMENT shall be resolved by arbitration pursuant to the terms of Exhibit D
attached hereto.

15.10  Bankruptcy All rights and licenses granted under or pursuant to this
       ----------
Agreement are, and shall otherwise be, deemed to be, for purposes of Section
365(n) of the U.S. Bankruptcy Code, licenses of rights to "intellectual
property" as defined under Section 101(52) of the U.S. Bankruptcy Code and any
similar provision protecting licensee's rights under applicable bankruptcy rules
and regulations under English law. The Parties to this Agreement shall retain
and may fully exercise all of their respective rights and elections under the
U.S. Bankruptcy Code. The Parties further agree that, in the event of the
commencement of bankruptcy proceeding by or against a party licensor under the
U.S. Bankruptcy Code or its English law equivalent, the licensee shall be
entitled to a complete duplicate of (or complete access to, as appropriate) any
such intellectual property and all embodients of such intellectual property, and
same, if not already in its possession, shall be promptly delivered to the
licensee (a) upon any such commencement of a bankruptcy proceeding upon written
request therefor by the licensee, unless the licensor elects to continue to
perform all of its obligations under this AGREEMENT, or (b) if not delivered
under (a) above, upon the rejection of the AGREEMENT by or on behalf of the
licensor upon written request therefor by the licensee, provided, however, that
upon the licensor's (or its successor's) written notification to the licensee
that it is again willing and able to perform all of its obligations under this
AGREEMENT, the licensee shall promptly return all such tangible materials to the
licensor, but only to the extent that the licensee does not require continued
access to such materials to enable the licensee to perform its obligations under
this AGREEMENT.

                                       42
<PAGE>

15.11  Execution This AGREEMENT may be executed in multiple counterparts each
       ---------
of which shall be deemed an original and which together shall constitute one and
the same instrument.

           IN WITNESS WHEREOF, the parties hereto have executed this Agreement.

       ACCEPTED AND AGREED TO BY:

       G.D. SEARLE & CO.                          CAMBRIDGE ANTIBODY
                                                  TECHNOLOGY LIMITED

       By:__________________________              By:___________________________

       Title:                                     Title:

       Date:________________________              Date:

                                       43
<PAGE>

                                   EXHIBIT A

                         CAT BACKGROUND PATENT RIGHTS

Key patents relating to the CAT Library technology:

Winter II - PCT/GB89/01344 - Cloning of a library of immunoglobulin V-gene
sequences for expression of a repertoire of immunoglobulin variable domains,
using appropriate primers in a PCR reaction; expression libraries containing
repertoires of nucleic and acid sequences each encoding at least part of an
immunoglobulin variable domain.

This patent has been granted in Europe and Australia, and is pending in the US,
Canada and Japan.

McCafferty et al. - PCT/GB91/01134 - Methods for producing fuctional, single-
chain Fv antibody fragments on the surface of bacteriophage particles.

This patent has been granted in Europe, Australia and the US, and is pending in
Canada and Japan.

Griffiths et al. - US 5885793 - Isolation of human antibodies to human proteins
by filamentous phage display and to methods for producing human antibodies.

This patent was granted in the US on 23 March 1999

                                       44
<PAGE>

                                   EXHIBIT B

                           CAT SUBTRACTED LIBRARIES

[***]

                                       45
<PAGE>

                                   EXHIBIT C

                               RESEARCH PROTOCOL

SEARLE will bring to the collaboration a certain number of genes or partial gene
sequences which, by virtue of previously derived biologic information (which
might include the assay of gene expression by immunocytochemistry in CAT's
standard set of human tissue samples using CAT ANTIBODIES, or other data
available in the literature or through CAT or SEARLE proprietary research),
offer promise as targets for the development of therapeutic antibodies, small
molecule therapeutics or as highly refined markers for use in preclinical and
clinical drug development.

For each gene a detailed research plan will be developed which will make full
use of CAT and SEARLE KNOW HOW, such as in vitro and in vivo assay systems,
proprietary databases and antibody engineering expertise.  For a therapeutic
target, such a RESEARCH PROGRAM would generally comprise the following:

[***]

                                       46
<PAGE>

                                   EXHIBIT F

Gene/Target Name                                Accession Number

[***]                                           [***]

                                       47
<PAGE>

                             PERFORMANCE GUARANTEE

In consideration of the execution of the foregoing Research and License
Agreement, CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC hereby guarantees to G. D.
SEARLE & CO. and its Affiliates, as principal and not as surety, the performance
by CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED of all of its obligations under the
foregoing Research and License Agreement.  This Guarantee is a guarantee of
performance and not of collection.

This Guarantee shall survive the expiration or other termination of the Research
and License Agreement or any assignment by G. D. SEARLE & CO. of its rights and
obligations under such agreement.

                                        CAMBRIDGE ANTIBODY
                                        TECHNOLOGY GROUP PLC

                                        By

                                        Its:

Date:   December 23, 1999
-------------------------

                                       48<PAGE>
                                                                    EXHIBIT 4.12

         (1)      CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc or CAMBRIDGE
                  ANTIBODY TECHNOLOGY LIMITED/1/

         (2)      [Executive]

                               SERVICE AGREEMENT

/1/ The Service Contracts of the Chief Executive Officer and the Finance
Director are with Cambridge Antibody Technology Group plc. The Service Contracts
of the Chief Technology Officer and the Medical Director are with CAT Limited.
<PAGE>

<TABLE>
<CAPTION>
                                   CONTENTS

Clause    Subject                                                           Page
<S>       <C>                                                               <C>

1.        Definitions and Interpretation                                    3

2.        Appointment                                                       3

3.        Duties                                                            4

4.        Outside Activities                                                5

5.        Remuneration                                                      5

6.        Expenses                                                          6

7.        Car                                                               6

8.        Holidays                                                          6

9.        Confidentiality                                                   7

10.       Inventions                                                        7

11.       Termination and sickness                                          8

12.       Obligations on termination                                        9

13.       Obligations after termination                                     10

14.       Amalgamation or Reconstruction                                    10

15.       Notices                                                           10

16.       Previous Contracts                                                11

17.       Governing Law                                                     11

18.       Statement of terms of employment                                  11
</TABLE>

                                       2
<PAGE>

<TABLE>
<S>       <C>                                                               <C>
19.       Waiver                                                            11

20.       Appendix                                                          12
</TABLE>

                                       3
<PAGE>

Dated:   10 February 1997

BETWEEN:

(1)               CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc/CAT Limited;

and

(2)               [EXECUTIVE]

1.     DEFINITIONS AND INTERPRETATION

1.1    In this Agreement the following words shall have the following meanings:-

       "Board"                    :    the board of directors of the Company;

       "Chairman"                 :    the Chairman of the board of directors;

       "Company"                  :    Cambridge Antibody Technology Group plc,
                                       a company incorporated under the laws of
                                       England and Wales with registered number
                                       3234033;

       "Executive"                :    [_________];

       "Group"                    :    the Company and any other company which
                                       from time to time is its Subsidiary or
                                       Holding Company or in which the Company
                                       controls not less than 25 per cent of the
                                       voting shares;

       "Holding Company"          :    has the same meaning as given to it in
                                       Section 736 of the Companies Act 1985;

       "Remuneration Committee"   :    the Remuneration Committee of the Board;

       "Subsidiary"               :    has the same meaning as given to it in
                                       Section 736 of the Companies Act 1985.

1.2    The headings in this Agreement are for convenience only and are not to be
       used as an aid to construction of this Agreement.

                                       4
<PAGE>

1.3    References to provisions of statutes, rules or regulations shall be
       deemed to include references to such provisions as amended, modified or
       re-enacted from time to time.

2.     APPOINTMENT

2.1    The Company shall engage the Executive and the Executive shall serve the
       Company as its [___________] or in such other comparable capacity as the
       Company may from time to time reasonably require, it being understood
       that this will not result in any reduction in the status of the
       Executive. The Executive shall also join the Board.

2.2    The employment of the Executive commenced on [_________] and shall
       continue until terminated as provided in this Agreement.

3.     DUTIES

3.1    The Executive shall:

       3.1.1    except during holidays (Clause 8 of this agreement),
                unavoidable absence due to sickness, or other imperative
                cause, or when performing duties under any non-executive
                directorship approved by the Board under Clause 4 of this
                agreement, devote the whole of his time and attention and
                abilities during normal business hours and at such other times
                as the Company or his duties may reasonably require to the
                business of the Company and undertake such duties and exercise
                such powers and authorities in relation to the Company and the
                business of the Company as the [Chief Executive
                Officer/Board]2 shall from time to time assign to or vest in
                the Executive;

       3.1.2    in the discharge of such duties and in the exercise of such
                powers conform to, observe and comply with all resolutions and
                directions from time to time made or given by the [Chief
                Executive Officer/Board];

       3.1.3    report directly to the [Chief Executive Officer/Board] in such
                a manner and so often as the [Chief Executive Officer/Board]
                may from time to time require;

       3.1.4    faithfully and diligently serve the Company and use his best
                endeavours to maintain, extend, develop and promote its
                interests;

       3.1.5    use his best endeavours to promote the interests and the welfare
                of the Company and to develop and maintain the business of the
                Company;

       3.1.6    not engage in any activity which will detract from the proper
                performance of his duties;

________
/2/ If the Service Contract is with the Chief Executive Officer, then the Board
is used, otherwise, the Chief Executive Officer is used.

                                       5
<PAGE>

       3.1.7    at all times perform his duties with proper skill and care.

3.2    The Executive may be required in pursuance of his duties hereunder:

       3.2.1    to perform services not only for the Company but also for any
                other company in the Group and without further remuneration
                (except as otherwise approved by the Remuneration Committee and
                agreed in writing) to accept such offices in other companies in
                the Group as the Company may from time to time reasonably
                require and if such offices carry any fee or other remuneration
                the Executive will immediately pay or direct payment of it to
                the Company;

       3.2.2    to work at such places within the United Kingdom as the Company
                may require; and

       3.2.3    to travel to such places whether in or outside the United
                Kingdom by such means and on such occasions as the Company may
                from time to time reasonably require, such travel to be in
                accordance with the terms of the Company's travel policy for the
                time being.

3.3    Any duties undertaken by the Executive as a director of the Company or
       any other Company in the Group are subject to the Articles of Association
       of the relevant company for the time being.

3.4    The Company may at any time after serving or receiving notice to
       terminate this Agreement suspend the Executive from the performance of
       his duties and/or exclude him from any premises of the Company or any
       company in the Group and/or appoint a replacement to perform some or all
       of his duties instead of him and/or require him to resign as a director
       of the Company and from any office or appointment held under clause 3.2.1
       but salary and other contractual benefits will not cease to be payable or
       provided by reason only of that suspension and/or exclusion. This clause
       shall not affect the general right of the Company to suspend the
       Executive for a limited period not to exceed 20 consecutive working days
       for the purposes of conducting a disciplinary hearing and/or
       investigation.

4.     OUTSIDE ACTIVITIES

       Except as a representative of the Company or with the previous written
       approval of the Chairman the Executive shall not during his full-time
       employment by the Company be directly or indirectly employed, engaged,
       concerned or interested in any capacity in any other trade or business
       (whether paid or unpaid) save as a holder of the legal or equitable
       interest (as defined by Schedule 13 of the Companies Act 1985) in the
       shares or securities of a company any of whose shares or securities are
       quoted or dealt in on any recognised Stock Exchange provided that any
       such holding shall not exceed three per cent (3%) of the whole or any
       class of the issued share capital of the company concerned.

                                       6
<PAGE>

       The Board will consider any reasonable request from the Executive to
       serve as a non-executive director on the board(s) or other companies.

5.     REMUNERATION

5.1    The Company shall pay to the Executive by way of remuneration for his
       services (less deductions for tax and national insurance contributions) a
       basic salary of [_____] pounds sterling per annum/3/ to be paid by equal
       monthly instalments in arrears on the last working day of each month.

5.2    The quantum of the remuneration of the Executive will be reviewed
       annually by the Remuneration Committee with effect for the first time
       from 1 October 1997.

5.3    Subject to the Executive satisfying the medical criteria of the insurer
       and provided that cover is available at a reasonable premium (as
       determined by the Remuneration Committee) for an individual of the
       Executive's age, the Company will insure the life of the Executive from
       year to year during the term of his employment under and on the terms of
       the Company's Personal Accident Scheme (described in the Company's
       Employee Benefits Handbook) or any successor scheme. The Company will
       also provide disability cover under and on the terms of its Income
       Protection Scheme (described in the Company's Employee Benefits
       Handbook).

5.4    The Company will contribute ten per cent (10%) of the Executive's basic
       salary applicable at the time to the Company's Group Personal Pension
       Scheme. If at any time legislation or regulation limits or prohibits such
       contribution, the Company will contribute up to the amount permitted and
       will make available any surplus of the said ten per cent (10%) to the
       Executive for investment in a pension fund agreed between the Company and
       the Executive, provided that the total cost to the Company under this
       clause 5.4 shall not in any circumstances exceed ten per cent (10%) of
       the Executive's basic salary.

5.5    The Executive shall not, except with the prior approval of the
       Remuneration Committee, accept any bonus, commission, contract, award,
       gift in money or in kind from any person in excess of (pound)100 for any
       single gift and (pound)250 in aggregate in any calendar year, except the
       Company, as an inducement or reward for any act or forbearance or in
       connection with any matter of business transacted by or on behalf of the
       Company.

5.6    The Company shall contribute up to one thousand five hundred pounds
       ((Pounds)1,500) per annum towards the cost of providing private medical
       insurance cover, approved by the Company, for the benefit of the
       Executive and his immediate family.

6.     EXPENSES

_____________
/3/ The salary for each of the directors is disclosed in the text of the
registration statement.

                                       7
<PAGE>

6.1    The Executive shall be entitled to be repaid all travelling, hotel and
       other expenses reasonably and properly incurred by him in the performance
       of his duties under this Agreement, subject to the production to the
       Company of supporting vouchers and documents.

6.2    The Executive shall use any credit card or similar facility provided to
       him by the Company solely for payment of expenses reasonably and properly
       incurred by him in the performance of his duties under this Agreement.

6.3    The Company shall reimburse to the Executive all of the rental and call
       charges of a facsimile at his home and the costs of installing and
       operating a business telephone line at his home for the performance of
       his duties.

6.4    The Company shall reimburse the Executive his membership fees for agreed
       professional societies and agreed professional subscriptions.

6.5    The Company shall reimburse the Executive for reasonable legal fees,
       estate agents' commission, advertising costs, mortgage redemption costs
       and removal charges incurred by the Executive in relocating himself and
       his family to the vicinity of the Company's premises if such a move takes
       place within two (2) years of his joining the Company.

7.     CAR

7.1    The Company shall pay to the Executive a non-pensionable allowance at
       such rate as the Remuneration Committee may from time to time determine
       in lieu of the provision to him of a company car. The Executive agrees
       that he shall procure the availability at all times of a car which is
       suitable (in terms of age, make, specification and model) for use by him
       on Company business, that he will ensure that the car is properly
       insured, maintained and repaired for such use and will forthwith report
       to the Company any accidents in which he is involved on Company business.
       The Company will reimburse the Executive for any business mileage at the
       rate approved by the Inland Revenue for such car.

8.     HOLIDAYS

8.1    The Executive shall be entitled to twenty five (25) working days' holiday
       (in addition to public holidays) in each holiday year at full salary to
       be taken at such time or times as may be approved by the [Chief Executive
       Officer/Chairman]. The Company's holiday year commences 1 January.
       Holidays not taken (up to a maximum of ten (10) days of the holiday
       entitlement) may be carried over to the subsequent year. Holiday
       entitlement during the first year in which the Executive shall have
       joined shall be on a pro-rata basis.

8.2    Upon termination of the Executive's engagement hereunder (otherwise
       than in pursuance of clause 11.1 or clause 11.2) his entitlement to
       holiday will be calculated on the basis of one twelfth (1/12) of his
       annual holiday entitlement for each completed calendar month of service

                                       8
<PAGE>

       in the then current holiday year and payment in lieu will be made for
       any whole day's holiday not taken at the date of such determination.
       The number of days resulting from this calculation will be multiplied
       by one two hundred and sixtieth (1/260) of the Executive's annual
       salary.

                                       9
<PAGE>

9.       CONFIDENTIALITY

9.1      The Executive shall not make use of, divulge or communicate to any
         person (save in the proper performance of his duties under this
         Agreement) any of the trade secrets or other confidential information
         of or relating to the Company or any other company in the Group which
         he may have received or obtained while in the service of the Company or
         any other company in the Group. This restriction shall continue to
         apply after the termination of the employment of the Executive without
         limit in point of time.

9.2      For the purposes of clause 9, confidential information shall include,
         but shall not be limited to:

         9.2.1    information relating to any reagents, chemical compounds or
                  biological material being used or developed by the Company or
                  any other company in the Group;

         9.2.2    all technical, biotechnical, biological or biochemical
                  information relating to the research or work being carried out
                  by the Company or any other company in the Group;

         9.2.3    inventions relating to past, existing and future research
                  and/or products;

         9.2.4    lists of customers and suppliers and details of contracts with
                  customers and suppliers of the Company or any company in the
                  Group; and

         9.2.5    information supplied to the Company or any company in the
                  Group or to the Executive in confidence by customers.

9.3      The undertakings in this clause 9 shall not apply to:

         9.3.1    information that at the time it is received or obtained by the
                  Executive is published or otherwise generally available to the
                  public;

         9.3.2    information which after it is received or obtained by the
                  Executive is published or otherwise becomes generally
                  available to the public, otherwise than through any wrongful
                  act or omission on the part of the Executive;

         9.3.3    information rightly acquired from a third party who did not
                  obtain it under a pledge of secrecy to the Company or any
                  other company in the Group;

         9.3.4    information ordered to be disclosed by a court of competent
                  jurisdiction or other wise required by law to be disclosed.

9.4      The obligations of the Executive under this clause 9 shall be in
         addition to and not in substitution for any implied obligations imposed
         upon him by law in relation to the use or disclosure of confidential
         information.

                                       10
<PAGE>

10.      INVENTIONS

10.1     in this clause 10 the words "Intellectual Property" shall include
         patents, trade marks (whether registered or unregistered), registered
         or unregistered design, utility models, copyrights (including design
         copyrights), applications for any of the foregoing and the right to
         apply for them in any part of the world, discoveries, creations,
         inventions (or improvements upon or additions to an invention),
         confidential information, know-how and any research effort relating to
         any of the foregoing, business names (whether registrable or not),
         moral rights and any similar rights in any country.

10.2     If the Executive makes, discovers or creates Intellectual Property in
         the course of his duties under this Agreement the parties agree that,
         in this respect, the Executive has a special obligation to further the
         interests of the Company.

10.3     Subject to the provisions of the Patents Act 1977 and the Copyright,
         Designs and Patents Act 1988, if at any time during his employment
         under this Agreement the Executive makes, creates or discovers or
         participates in the making, creation or discovery of any Intellectual
         Property relating to or capable of being used in the business of the
         Company or in the business of any other company within the Group, he
         shall immediately communicate full details of such Intellectual
         Property to the Company and such Intellectual Property shall be the
         absolute property of the Company. At the request and expense of the
         Company, the Executive shall give and supply all such information,
         data, drawings and assistance as may be requisite to enable the Company
         to exploit such Intellectual Property to the best advantage and shall
         execute all documents and do all acts and things which may be necessary
         or desirable for obtaining patent or other protection for such
         Intellectual Property in such parts of the world as may be specified by
         the Company and for vesting the same in the Company or as it may
         direct. The Executive hereby irrevocably waives all moral rights
         related to the works covered by this Clause 10.3, the copyright of
         which belongs to the Company.

10.4     The Executive irrevocably appoints the Company to be his attorney in
         his name and on his behalf to sign, execute or do any such instrument
         or thing and generally to use his name for the purpose of giving the
         Company (or its nominee) the full benefit of the provisions of this
         clause and, in favour of any third party, a certificate in writing
         signed by any director or the Company Secretary that any instrument or
         act falls within the authority conferred by this clause shall be
         conclusive evidence that such is the case.

11.      TERMINATION AND SICKNESS

11.1     This Agreement may be terminated immediately by the Company by notice
         in writing if the Executive shall:

                                       11
<PAGE>

         11.1.1   have committed any breach and after warning in writing either
                  repeated or continued that breach of his obligations
                  hereunder; or

         11.1.2   be involved in any act, matter or thing or engage in any
                  conduct which in the reasonable opinion of the [Chief
                  Executive Officer/Board] might bring the Executive or the
                  Company or any company in the Group into disrepute or might be
                  detrimental to the Company or any company in the Group or
                  their businesses; or

         11.1.3   voluntarily resign as a director of the Company without good
                  cause after having been appointed to that office; or

         11.1.4   be guilty of dishonesty whether or not in connection with or
                  referable to his employment under this Agreement; or

         11.1.5   be convicted of any criminal offence (excluding an offence
                  under road traffic legislation, for which the Executive is not
                  sentenced to any term of imprisonment, whether suspended or
                  not); or

         11.1.6   become of unsound mind or a patient under the Mental Health
                  Act 1983; or

         11.1.7   become unable to pay his debts as they fall due, make any
                  compensation or arrangement with his creditors or become
                  bankrupt; or

         11.1.8   have been disqualified from being a director under the Company
                  Directors Disqualification Act 1986.

11.2     If the Executive shall during the continuance of this Agreement be
         incapacitated by ill-health or accident from performing his duties
         hereunder (and he shall if required produce to the Company evidence of
         such incapacity) for a period or periods aggregating ninety (90)
         working days or more in any period of twelve (12) months the Company
         may by written notice to the Executive forthwith or as from a future
         date specified in the notice discontinue payment in whole or in part of
         his remuneration and other benefits under clause 5 hereof until such
         incapacity shall cease or (whether or not his remuneration and benefits
         shall have been discontinued as aforesaid) terminate this Agreement by
         giving such notice as the Executive is then entitled to receive under
         Section 86 of the Employment Rights Act 1996. Otherwise the
         remuneration and benefits shall continue to be payable to the Executive
         under clause 5 notwithstanding such incapacity but the Company shall be
         entitled to set off or deduct therefrom the amount of any statutory
         sick pay and/or sickness related benefit to which the Executive is
         entitled under Social Security legislation for the time being in force.

         The Company shall not have any liability to pay any benefit to the
         Executive under any scheme unless it receives payment of the benefit
         from the insurers of the benefits under the scheme.

                                       12
<PAGE>

11.3     Either party may terminate this Agreement by giving not less than
         twelve (12) months notice in writing to that effect expiring at any
         time.

11.4     The Company shall be entitled to pay salary in its absolute discretion
         in lieu of notice or of an unexpired period of notice. For the
         avoidance of doubt, this right shall apply where the notice is given by
         the Company or the Executive. Any payment in lieu of notice shall
         consist of a sum equivalent to the Executive's basic salary (at the
         rate applicable at the date notice is given) and including any benefits
         enjoyed by the Executive at that time, for the notice period or any
         unexpired period of notice and shall be subject to such deductions for
         tax and national insurance as the Company is required to make.

11.5     The Agreement shall automatically terminate when the Executive reaches
         the age of sixty-five (65).

12.      OBLIGATIONS ON TERMINATION

         Upon the giving of notice pursuant to clause 11.2 above or termination
         of this Agreement for any other reason the Executive shall:

12.1     forthwith or within seven days of a request from the Company resign
         from office as a director of the Company and all offices held by him in
         any other companies in the Group and his membership of any organisation
         acquired by virtue of his tenure of any such office, and should he fail
         to do so he hereby irrevocably authorises the Company Secretary for the
         time being in his name and on his behalf to sign any documents and do
         anything necessary or requisite to give effect thereto; and

12.2     deliver to the Company's premises during normal business hours all
         property in his possession or under his control belonging to the
         Company or any other company in the Group including but not limited to
         keys, security and computer passes, computer hardware, facsimile
         machines and all documents and other records (whether on paper,
         magnetic tape or in any other form and including correspondence, lists
         of clients or customers, notes, memoranda, software, plans, drawings
         and other documents and records of whatsoever nature and all copies
         thereof) made or compiled or acquired by the Executive during his
         employment hereunder and concerning the business, finances or affairs
         of the Company or any other company in the Group or its clients or
         customers; and

12.3     execute forthwith stock transfer forms in favour of the Company or any
         other company in the Group or such nominee as they shall appoint in
         respect of any nominee shares held by the Executive on behalf of the
         Company or any company in the Group.

13.      OBLIGATIONS AFTER TERMINATION

                                       13
<PAGE>

13.1     The Executive shall not, so as to compete with the Company or any
         company in the Group and/or to harm the goodwill of the Company or any
         company in the Group, during the twelve (12) months after the
         termination of this Agreement, directly or indirectly, canvass or
         solicit business from or do business with any customer or supplier of
         the Company or any company in the Group or any other person with whom
         the Executive shall have had material dealings in the course of his
         duties hereunder in the twelve months (12) immediately preceding the
         termination of this Agreement.

13.2     The Executive shall not, during the twelve (12) months after the
         termination of this Agreement, directly or indirectly induce or seek to
         induce any employee of the Company or any company in the Group, who was
         such an employee at the termination of this Agreement employed in an
         Executive, Vice Presidential, Managerial or Senior Scientist
         positionand with whom the Executive shall have had material dealings in
         the course of his duties hereunder in the twelve (12) months
         immediately preceding the termination of this Agreement, to leave his
         or her employment, whether or not this would be a breach of contract on
         the part of the employee.

13.3     The Executive shall not, during the six (6) months after the
         termination of this Agreement, carry on or be interested in business in
         competition with the Company or any company in the Group, whether as
         principal, agent, director, partner, proprietor, employee or otherwise.

13.4     Each of the restrictions contained in this clause 13 are considered
         reasonable by the Company and the Executive and are intended to be
         separate and severable. In the event that any of the restrictions shall
         be held void, but would be valid if part of the wording thereof were
         deleted, such restriction shall apply with such deletion as may be
         necessary to make it valid and effective.

14.      AMALGAMATION OR RECONSTRUCTION

         If at any time the Executive's employment is terminated in connection
         with any reconstruction or amalgamation of the Company or its
         subsidiaries (whether by winding up or otherwise) and the Executive
         receives an offer on terms no less favourable to him overall than the
         terms of this Agreement from any company involved in such
         reconstruction or amalgamation, the Executive shall have no claim
         whatsoever against the Company or any such subsidiary arising out of
         such termination if he shall have refused to accept such offer of
         employment. The provisions of this clause are without prejudice to the
         operation, statute or statutory regulations in appropriate cases.

15.      NOTICES

         Any notice to be given under this Agreement shall be given in writing
         and may be sent addressed in the case of the Company to its registered
         office or principal place of business for the time being and in the
         case of the Executive to him at his last known place of residence or

                                       14
<PAGE>

         given personally and any notice given by post shall be deemed to have
         been served at the expiration of forty-eight (48) hours after the same
         was posted. Notice may also be given by facsimile in which case it
         shall be deemed to have been served twelve (12) hours after the same
         was transmitted.

16.      PREVIOUS CONTRACTS

         This Agreement is in substitution for any previous contract of service
         or for services between the Company or any company in the Group and the
         Executive which shall be deemed to have been terminated by mutual
         consent as from the commencement of his engagement hereunder.

17.      GOVERNING LAW

         This Agreement shall be governed by and construed in accordance with
         English law.

18.      STATEMENT OF TERMS OF EMPLOYMENT

         The information in this Agreement and Appendix hereto constitutes a
         written statement of the terms of employment of the Executive in
         compliance with the provisions of Section 2 of the Employment Rights
         Act 1996.

19.      WAIVER

         The waiver of any right the Company may have by virtue of this
         Agreement shall not constitute a continuing or repeated waiver or of
         any other right.

EXECUTED AS A DEED
BY THE COMPANY
ACTING BY:-                         ..........................
                                    Director

                                    ..........................
                                    Secretary

EXECUTED AS A DEED
BY THE EXECUTIVE:-                  ..........................

                                       15
<PAGE>

                                    Signed

                                    ..........................
                                    Name

WITNESSED BY:-                      ..........................
                                    Signed

                                    Name:

                                    Address:

                                       16
<PAGE>

                                   APPENDIX

(1)    Date of Commencement of Period of Continuous Employment - The Executive
       has been in the employment of the Company (including reckonable service
       with its subsidiary or associated companies) since [___________].

(2)    Rate of Remuneration and the intervals at which it is paid is specified
       in clause 5.

(3)    There are no specific terms and conditions relating to hours of work
       except as provided in clause 3.1.

(4)    The terms and conditions relating to holidays are contained in clause 8
       and those relating to sickness are contained in clause 11.2.

(5)    The Company operates a pension scheme which the Executive is entitled to
       join - clause 5.6. A contracting-out certificate is not in force in
       respect of the Executive's employment.

(6)    Particulars as to the length of notice to terminate are contained in
       clause 11.

(7)    There are no disciplinary rules applicable to the Executive except as
       provided in this Agreement and if the Executive is dissatisfied with
       any disciplinary decision relating to him he should apply orally or in
       writing to the [Chief Executive Officer/Board].

(8)    Any application for the purpose of seeking redress of any grievance
       relating to the Executive's employment should be made either orally or
       in writing to the [Chief Executive Officer/Board].

(9)    There are no collective agreements relevant to the employment of the
       Executive.

                                       17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]